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Report of five novel and one recurrent COL2A1
mutations with analysis of genotype-phenotype
correlation in patients with a lethal type II
collagen disorder
Geert R Mortier, MaryAnn Weis, Lieve Nuytinck, Lily M King, Douglas J Wilkin,
Anne De Paepe, Ralph S Lachman, David L Rimoin, David R Eyre, Daniel H Cohn
Abstract
Achondrogenesis II-hypochondrogenesis
and severe spondyloepiphyseal dysplasia
congenita (SEDC) are lethal forms of
dwarfism caused by dominant mutations
in the type II collagen gene (COL2A1). To
identify the underlying defect in seven
cases with this group of conditions, we
used the combined strategy of cartilage
protein analysis and COL2A1 mutation
analysis. Overmodified type II collagen
and the presence of type I collagen was
found in the cartilage matrix of all seven
cases. Five patients were heterozygous for
a nucleotide change that predicted a
glycine substitution in the triple helical
domain (G313S, G517V, G571A, G910C,
G943S). In all five cases, analysis of carti-
lage type II collagen suggested incorpora-
tion of the abnormal á1(II) chain in the
extracellular collagen trimers. The G943S
mutation has been reported previously in
another unrelated patient with a strikingly
similar phenotype, illustrating the possi-
ble specific eVect of the mutation. The
radiographically less severely aVected pa-
tient was heterozygous for a 4 bp deletion
in the splice donor site of intron 35, likely
to result in aberrant splicing. One case
was shown to be heterozygous for a single
nucleotide change predicted to result in a
T1191N substitution in the carboxy-
propeptide of the proá1(II) collagen chain.
Study of the clinical, radiographic, and
morphological features of the seven cases
supports evidence for a phenotypic con-
tinuum between achondrogenesis II-
hypochondrogenesis and lethal SEDC and
suggests a relationship between the
amount of type I collagen in the cartilage
and the severity of the phenotype.
(J Med Genet 2000;37:263–271)
Keywords: type II collagen disorders; achondrogenesis
II-hypochondrogenesis; spondyloepiphyseal dysplasia
congenita; COL2A1
Several heritable osteochondrodysplasias have
now been recognised as members of the family
of type II collagen disorders, all of which result
from dominant mutations in the COL2A1
gene.1–4 Phenotypes within this group range
from severe lethal dwarfism at birth to
relatively mild conditions with precocious
osteoarthrosis and little or no skeletal growth
abnormality.2 Achondrogenesis II-hypochond-
rogenesis and lethal spondyloepiphyseal dys-
plasia congenita (SEDC) represent the more
severe end of the spectrum.1 5–7 These entities
are characterised by severe disproportionate
short stature of prenatal onset. The distinction
between these phenotypes is mainly based
upon clinical, radiographic, and morphological
features but considerable phenotypic overlap
often hampers proper classification.1 6–8
All of the previously reported cases of
achondrogenesis II-hypochondrogenesis in
which the molecular defect was found were
heterozygous for a mutation in the COL2A1
gene resulting in a glycine substitution in the
triple-helical domain of the proá1(II) collagen
chain.9–16 Biochemical analysis of cartilage usu-
ally showed the presence of type I collagen and
post-translationally overmodified type II colla-
gen. Studies on cultured chondrocytes from
one case of hypochondrogenesis with a G913C
mutation showed lack of secretion of type II
collagen in the medium.16 Mutations reported
in cases of SEDC are more heterogeneous.
Single amino acid substitutions, deletions, or
duplications in the triple helical domain of the
proá1(II) collagen chain have been
reported.17–24
The aim of this study was to identify the
mutation in the COL2A1 gene in seven cases of
achondrogenesis II-hypochondrogenesis or se-
vere SEDC based on the results of the
biochemical analysis of cartilage tissue. Instead
of performing a “head to tail” mutation analy-
sis of the entire gene, we first started screening
those regions of the COL2A1 gene in which a
mutation was most likely to reside, based on
the electrophoretic properties of the extracted
cartilage collagen. The phenotype of each case
was studied in relation to the molecular and
biochemical findings and compared with other
reported cases of achondrogenesis II-
hypochondrogenesis and SEDC in which a
COL2A1 mutation was identified.
Materials and methods
PATIENTS
The seven patients in this study were referred
in the period 1982 to 1991 to the International
Skeletal Dysplasia Registry at Cedars-Sinai
Medical Center, Los Angeles for diagnosis.
The clinical features and radiographs were sent
to the Registry for evaluation and tissue speci-
mens, taken during necropsy, were collected
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for morphological, biochemical, and molecular
studies. All patients were sporadic. Parental
DNA samples were not available.
PROTEIN ANALYSIS
Cartilage stored at −70°C was used. For analy-
sis of pepsin solubilised collagen, cartilage was
extracted, washed, and digested with pepsin as
described previously.11 The resulting collagen
type II molecules were analysed by sodium
dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Human epiphyseal
cartilage collagen from a 4 day old neonate
without signs of a skeletal dysplasia was used as
a control. For peptide analysis, cartilage was
digested with cyanogen bromide (CB) and the
resulting collagen CB peptides were analysed
by SDS-PAGE and stained with Coomassie
blue as described previously.11
NUCLEIC ACID ANALYSIS
Genomic DNA was isolated from cultured skin
fibroblasts by standard procedures. PCR am-
plifications were performed in 25 µl reactions
containing 100 ng of genomic DNA, 2 U Taq
DNA polymerase, 2.5 pmol of each primer,
200 µmol/l of each dNTP, 2 mmol/l MgCl2, 10
mmol/l Tris-HCl, pH 8.3, and 50 mmol/l KCl.
The amplification conditions consisted of an
initial two minutes at 95°C followed by 36
cycles of 95°C for one minute, 60°C for one
minute, and 72°C for one minute, followed by
a nine minute incubation at 72°C. Primer
sequences were 5'-CTGTTCTCACTCACT
GCCTC-3' and 5'-GGATACCATGTGACC
TCAG-3' for exon 22; 5'-GGTTGATCACTT
CTTGGTG-3' and 5'-CTCAGTGGGACTC
CAGGCTAC-3' for exon 31; 5'-GTGCCC
GGCTGAGGCGGCTG-3' and 5'-TCCTAA
TGCCCAGCAGTCCAG-3' for exon 33; 5'-
ACCTTCTTACCCCAGCTCTTC-3' and 5'-
GGCCTCGGGCAGAGCCAGGC-3' for
exon 35; 5'-CCCTGACCTGACTCAATC
GG-3' and 5'-AGGAGGCCTCGGGAAGT
CCC-3' for exon 46; and 5'-TCCTCTGA
GCTTGCTCCACTC-3' and 5'-TCCTGTC
ACTTTAGGACCTG-3' for exon 51. Primer
sequences for the other exons are available on
request. The PCR generated fragments were
examined on non-denaturing 6% polyacryla-
mide gels (29:1 acrylamide:bis ratio) in 1 ×
TBE buVer. For single strand conformation
polymorphism (SSCP) analysis, 5 µCi of
á-[32P] dCTP was added to the PCR reaction
and the amount of unlabelled dCTP was
reduced to 2.5 µmol/l. Fragments were sepa-
rated by electrophoresis through MDE gels
(AT Biochem) for 11 hours at 3.5 W. The gels
were dried and exposed to x ray film for 48
hours at −70°C with an intensifying screen. For
heteroduplex analysis, PCR products were
denatured at 98°C for five minutes, renatured
for 60 minutes at 68°C, and loading buVer
(50% sucrose, 0.1% bromophenol blue, 0.1%
xylene cyanol in water) was added. The
samples were separated on MDE gels (1 ×
MDE gel supplemented with 10% glycerol in
0.6 × TBE) overnight at 250 V. The fragments
were visualised by ethidium bromide staining.
For DNA sequence analysis PCR generatedTa
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fragments were purified using a Qiaquick spin
PCR purification kit (Qiagen). The purified
fragments were either used for direct sequence
analysis or ligated into the TA cloning kit (In-
vitrogen) and sequenced using Sequenase 2.0
(USB). For direct sequencing, single stranded
DNA fragments were generated in a second
round of amplification using a purified aliquot
(2 µl) from the first PCR and only one of the
two primers (50 pmol).
CARTILAGE MORPHOLOGY
For light microscopy (LM), cartilage speci-
mens were fixed in 10% formalin and embed-
ded in methyl methacrylate. Five µm sections
were cut and stained as described previously.15
For electron microscopy (EM), cartilage speci-
mens were fixed in 2.5% glutaraldehyde, post-
fixed in osmium, and dehydrated and embed-
ded in Spurr resin. Thin sections were cut and
stained as described previously.15
Figure 1 Anteroposterior radiographs of patients
R86-153, R83-32, and R91-68. (A) Patient R86-153
represents a severe phenotype characterised by short tubular
bones with metaphyseal irregularities, minimal ossification
of vertebral bodies in the thoracic spine, hypoplastic iliac
wings with flat acetabular roofs, and short ribs. (B) Patient
R83-32 shows an intermediate phenotype. (C) Patient
R91-68 illustrates a milder phenotype with normal
metaphyses of shortened tubular bones, flattened but
normally ossified vertebral bodies, normal acetabular roofs,
and a less narrow chest.
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Results
The diagnosis of a lethal type II collagen disor-
der was made in each of the patients based on
the clinical, radiographic, and morphological
features (table 1, fig 1).1 Significant findings on
which the diagnosis was based included the
following. (1) Clinical: moderate to severe
short limbed dwarfism at birth with respiratory
problems owing to a small thorax; cleft palate.
(2) Radiographic: incomplete ossification of
the vertebral bodies; severe shortening of the
long bones and ribs; flared iliac wings; absent
ossification of pubic bones, talus, and cal-
caneus. (3) Morphological: hypervascular rest-
ing cartilage; chondrocytes with inclusion bod-
ies (LM) or dilated cisternae of the rough
endoplasmic reticulum (RER) containing
granular material (EM); disorganised growth
plate characterised by extension of hyper-
trophic cells into the primary trabeculae.
SDS-PAGE of cyanogen bromide (CB)
digested cartilage from patient tissues showed
slowly migrating, post-translationally over-
modified type II collagen CB peptides not seen
in the control (fig 2A). The cases varied in their
degree of overmodification as best shown by
the extent to which á1(II) CB10 was retarded.
CB10 was most retarded for R85-109 and
R86-153 and less so for R86-6. From R86-6,
however, peptide á1(II) CB11 was noticeably
retarded compared with control CB11. A dou-
blet for CB10 was visible in R82-121 and an
abnormally broad band for CB10 was apparent
in R91-68. These observations suggested
where along the proá1(II) collagen molecule
the mutation may lie, since post-translational
overmodification of the procollagen molecules
starts at or near the mutation site and proceeds
in an amino-terminal direction. For R86-6, a
defect in the middle of the triple helix, amino-
terminal to CB10 was postulated, whereas for
the other patients a defect within or carboxyl-
terminal to CB10 was most likely (fig 2C).
SDS-PAGE of pepsin extracted collagen from
the patient cartilage also showed slowly migrat-
ing, overmodified á1(II) chains in most cases
compared with the control (fig 2B). The pepsin
extract of R85-109 showed a retarded â
component not present in the control extract.
The band disappeared on reduction with
dithiothreitol (not shown) indicating that it was
a disulphide bonded â dimer. Type I collagen
was also present in many samples as seen from
the CB peptide patterns and from the charac-
teristic pattern of three â dimer bands evident
in the pepsin digests. However, type I collagen
can be present in dissected samples of normal
human neonatal cartilage and the amount can
Figure 2 (A) SDS-polyacrylamide gel electrophoresis of cyanogen bromide (CB) peptides extracted from cartilage of each
patient and a control (4 day old neonate).The position of the CB peptides derived from control tissue is shown on the left
side for the á1(II) collagen chains and on the right side for the á1(I) and á2(I) collagen chains. The major á1(II) CB
peptides (CB10 and CB11) derived from patient’s tissue exhibit delayed mobility compared to the control. Based on the
intensity of the á2(I) CB3-5 peptides, type I collagen seems to be most abundant in patients R83-32, R86-153, and
R87-75. (B) SDS-polyacrylamide gel electrophoresis of pepsin extracted collagen from cartilage of each patient and a 4 day
old neonate (control) shows slowly migrating, overmodified á1(II) chains in most patients compared with the control. The
pepsin extract of R85-109 shows a retarded â component (arrow) not present in control extract. The position of normal
á1(II) chains, á1(I) chains, á2(I) chains, and â dimers is indicated on the right side. (C) Cyanogen bromide peptide map
of proá1(II) collagen. The corresponding exons and positions of methionine residues are shown at the top.
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vary between adjacent samples from the same
person. Based on the intensity of the á2(I)
CB3-5 peptides, type I collagen seemed to be
most abundant in patients R83-32, R86-153,
and R87-75 (fig 2A).
Since in the majority of the cases a defect
was postulated to reside within or carboxyl-
terminal to á1(II) CB10, the region corres-
ponding to exons 32-49 of the COL2A1 gene
was first targeted for mutation analysis (fig
2C). PCR generated genomic DNA fragments
for exons 32-49 were examined by SSCP
analysis. Primers were designed to include the
intron-exon boundaries in each exon amplifi-
cation. SSCP analysis showed an abnormal
pattern for fragments containing exon 46 in
patients R85-109 and R86-153 (fig 3), and for
fragments containing exon 35 in patient
R91-68 (fig 4). Direct sequence analysis of the
PCR products of exon 46 showed the
mutation in each of the two patients (fig 3).
Patient R85-109 was heterozygous for a G to
T transversion at the first nucleotide of exon
46. This change implied substitution of
glycine910 by cysteine and abolished a BstNI
restriction endonuclease site. Patient R86-153
was heterozygous for a G to A transition, pre-
dicted to result in substitution of glycine943 by
serine. The mutation abolished a cleavage site
for the restriction endonuclease MspI. Cleav-
age of the amplified DNA fragments with the
corresponding restriction endonucleases was
used to confirm that both patients were
heterozygous for the mutation (data not
shown). DNA sequence analysis of clones
containing exon 35 showed a 4 bp deletion at
the donor splice site of intron 35 in patient
R91-68 (fig 4). Neither cultured cells nor fro-
zen cartilage with which to test the prediction
of a splicing mutation were available.
For identification of the underlying defect in
the four other patients, the same region (exons
32-49) was first re-evaluated by heteroduplex
analysis and thereafter this analysis was ex-
tended to the other part of the triple helical
domain of the proá1(II) chain, corresponding
to exons 6-31. Only for patient R83-32 did
polyacrylamide gel electrophoresis of PCR
generate products containing exon 33 showing
both normal and more slowly migrating
fragments in a position which suggested inter-
allelic heteroduplexes. DNA sequence analysis
of clones containing exon 33 showed a G to C
transversion, implying substitution of glycine571
by alanine (fig 5). The mutation did not aVect
a cleavage site of any known restriction
endonuclease. Restudy of the earlier performed
SSCP analysis of amplified DNA fragments
containing exon 33 in patient R83-32 did not
show any abnormalities. Taking into account
the known lack of 100% sensitivity of SSCP
and heteroduplex analysis in mutation detec-
tion, direct sequence analysis of PCR amplified
genomic DNA fragments spanning the entire
triple helical domain was performed in the
remaining three patients. This study showed
that patient R86-006 was heterozygous for a G
to A transversion, predicted to result in substi-
tution of glycine313 by serine and that patient
R87-75 was heterozygous for a G to C
transition, predicted to result in substitution of
glycine517 by valine. These mutations did not
create or destroy a restriction endonuclease
cleavage site. No sequence changes in the triple
helical domain were found in patient R82-121.
However, in this patient, a C to A transversion
at the second nucleotide of codon 1191 was
identified. This single nucleotide change im-
plies substitution of threonine1191 by asparagine
(T1191N) in the carboxy-propeptide of the
proá1(II) collagen chain.
Discussion
Identification of the molecular defect in
patients with type II collagen disorders is usu-
ally a challenge because of the relatively large
size and complexity of the COL2A1 gene and
its main expression in cartilage. Cartilage is not
easily accessible, relatively acellular, and there-
fore a poor source of mRNA for cDNA synthe-
sis and analysis. Furthermore, suYcient
amounts of mRNA can often not be obtained
from cultured skin fibroblasts or lymphocytes
owing to low basal transcription of the gene.
Therefore, mutation analysis of the COL2A1
gene is often performed in the genomic DNA
in a “head to tail” fashion, which is time
consuming and laborious. In this study, we
used the opportunity of having cartilage tissue
for exploring the genetic defect in the COL2A1
gene in seven patients with a lethal type II
Figure 3 Identification of the COL2A1 mutation in patients R85-109 and R86-153.
(Top) SSCP analysis of amplified genomic DNA fragments containing exon 46. The
arrows indicate the abnormally migrating fragments from R86-153 (lane 1) and R85-109
(lane 5) compared to unrelated controls (lanes 2-4, 6). (Bottom) Partial nucleotide
sequence of exon 46 (upper case) and intron boundaries (lower case) containing both point
mutations. For R85-109, the G to T transversion predicts substitution of cysteine for glycine
at residue 910. For R86-153, the G to A transition implies substitution of serine for glycine
at residue 943. The restriction endonuclease cleavage sites disrupted by the mutation are
underlined.
ttcccagGGTCCTCAA...CCCGGCCCTCCTgtga
TGT
G910C
R85-109
AGC
G943S
R86-153
1 2 3 4 5 6
3'5'
BstNI Msp I
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collagen disorder. Those regions of the
COL2A1 gene in which a mutation was likely to
reside, based on the overmodification pattern
of the type II collagen CB peptides, were
screened first with SSCP and heteroduplex
analysis. Using these mutation detection meth-
ods, the underlying defect was found in four of
seven patients. The mutation in two other
patients (R86-6 and R87-75) could only be
identified with direct sequence analysis of PCR
amplified genomic DNA fragments.
The clinical, radiographic, and morphologi-
cal features of each patient were consistent with
the diagnosis of a lethal type II collagen disor-
der (table 1, fig 1). Significant overlap in
phenotype was noticed (table 1). With the
exception of patient R91-68, who represents
severe SEDC rather than achondrogenesis
II-hypochondrogenesis because of the com-
plete ossification of the spine and less severe
shortening of the long bones, all cases fell into
the achondrogenesis II-hypochondrogenesis
spectrum. In comparison to the other cases, the
phenotype of patient R82-121 was remarkable,
radiographically by more metaphyseal involve-
ment and clinically by absence of respiratory
insuYciency in the postnatal period. The baby
died at 13 months following seven months’
hospitalisation for severe, bilateral broncho-
pneumonia.
The results of the biochemical analysis
showed post-translationally overmodified type
II collagen in significant amounts in each
patient’s cartilage. This is consistent with
previous findings that mutant á1(II) chains can
be secreted and incorporated into the cartilage
matrix in patients with achondrogenesis II-
hypochondrogenesis or SEDC.11 15 18 24 How-
ever, in one case of hypochondrogenesis with a
G913C mutation, cultured chondrocytes failed
to secrete á1(II) chains in the medium.16 Type
I collagen was also present in the cartilage tis-
sue of each patient and appeared to be
increased in R83-32, R86-153, and R87-53,
who are the most severely aVected (table 1).
This might suggest a relationship between the
amount of type I collagen in the cartilage and
the severity of the phenotype. Probably in
response to insuYcient amounts of type II col-
lagen in the extracellular matrix, the chondro-
cytes produce and secrete more type I collagen
as a substitute. One study has shown that the
genes for type I collagen are expressed in
chondrocytes of a patient with hypochondro-
genesis.12 This would suggest that hypervascu-
larity of the cartilage is not the main explana-
tion for the presence of type I collagen in
cartilage of these patients.
It has been postulated that mutations in the
triple helical domain of procollagen á chains
delay the folding of the protein into the triple
helical conformation, which causes post-
translational overmodification of the protein
amino-terminal to the mutation site.25 The
availability of cartilage from each case allowed
us to screen for an overmodification pattern of
the CB peptides and so direct the molecular
analysis of the COL2A1 gene based on the bio-
chemical findings. Because of the slower
mobility of peptide CB10 in all but one of the
seven cases, it was decided to explore first the
domain of COL2A1 encoding exons 32-49 (fig
2C).
Analysing these exons using SSCP and
heteroduplex analysis, three patients (R86-
153, R85-109, and R83-32) were found to be
heterozygous for a missense mutation that pre-
dicted substitution of glycine in the triple heli-
cal domain of the á1(II) chain. Their pheno-
type resided at the more severe end of the
achondrogenesis II-hypochondrogenesis and
SEDC spectrum. In patient R85-109, with a
G910C mutation, the mutant á1(II) chains
were clearly expressed in the tissue as seen
from the presence of a reducible â dimer in the
pepsin extracted collagen (fig 2B). The peptide
patterns for R85-109 and R86-153 were
remarkably similar for both pepsin and CB
Figure 4 Identification of the COL2A1 mutation in patient R91-68. (Top) SSCP
analysis of amplified genomic DNA fragments containing exon 35. The arrow indicates the
abnormally migrating fragment from patient R91-68 (lane 5) compared to unrelated
controls (lanes 1-4, 6-8). (Middle) Identification of the 4 bp deletion at the splice donor of
intron 35. The sequence was determined after cloning of PCR products, containing exon 35
(upper case) and intron (lower case) boundaries, from the mutant and normal alleles. Five
of eight clones showed the 4 bp deletion at the splice donor of intron 35. (Bottom) The
IVS35+4delAGTG mutation implies skipping of exon 35.
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digests of tissue and it is notable that the
causative single amino acid substitutions
(G910C and G943S) were located near the
carboxyl-terminus of the triple helix. Interest-
ingly, the G943S mutation, identified in patient
R86-153, has been previously identified in
another, unrelated case.9 25 26 The recurrence of
the mutation could be explained by its
occurrence in the context of a CpG dinucle-
otide. The clinical, radiographic, and morpho-
logical features of both cases were almost iden-
tical illustrating the reproducible pathogenetic
eVects of this mutation (table 2).9 25 26
Analysis of the remaining exons 6-31 of the
triple helical domain of the proá1(II) collagen
chain by heteroduplex analysis did not identify
any abnormalities in patients R82-121, R86-6,
and R87-75. However, direct sequence analysis
of PCR amplified genomic DNA fragments
from this region showed a G313S mutation in
R86-6 and a G517V mutation in R87-75. As
predicted by the overmodification pattern of
the CB peptides, the mutation in R86-6 did
indeed reside amino-terminal to CB10. Com-
parable to patients R85-109 and R86-153, the
peptide patterns for patients R83-32 and
R87-75 were also quite similar. Again, the
mutations (G517V and G571A) were located
in the same region around the amino-terminal
border of CB10. Direct sequence analysis of
PCR generated genomic DNA fragments for
exons 6-49, spanning the entire triple helical
domain, did not show any abnormalities in
patient R82-121, despite the observed doublet
for CB10. The significance of the single nucle-
otide change, located in the carboxy-
Figure 5 Identification of the guanine to cytosine transversion in exon 33 of the COL2A1 gene for patient R83-32.
Partial nucleotide sequence of a clone containing the normal and mutant allele is shown. Three of 10 clones showed the
nucleotide change.
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Table 2 Clinical, radiographic, and morphological features of two patients with the G943S mutation in the COL2A1 gene
R86-153 Godfrey et al,25 26 Vissing et al9
Clinical
Sex Female Female
Birth length (gestational age) 29 cm (35 wk) 28 cm (32–33 wk)
Short limbs Yes Yes
Small thorax Yes Yes
Cleft palate Yes Yes
Respiratory insuYciency Yes Yes
Age at death 6 h 12 h
Radiographic
Long bones Marked shortening with metaphyseal irregularities Marked shortening with metaphyseal irregularities
Pelvis Small and flared iliac wings Small and flared iliac wings
Spine Only reasonable ossification in the thoracolumbar spine Only reasonable ossification in the thoracic spine
Thorax Small with short ribs Small with short ribs
Ossification of pubic bones No No
Ossification of ischia Yes No
Ossification of talus and calcaneus No No
Morphological
Resting cartilage Very hypervascular Increase in vascularity
Chondrocytes Inclusion bodies Dilated RER (EM)
Growth plate Very irregular with hypertrophic cells extending into the
metaphysis
Irregular with hypertrophic cells extending into the
metaphysis
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propeptide and predicted to result in substitu-
tion of threonine1191 by asparagine (T1191N),
remains unclear. Mutations in the carboxy-
propeptide of the proá1(II) collagen chain have
not been reported before in patients with a
lethal type II collagen disorder. However, single
amino acid substitutions in the carboxy-
propeptide of the proá1(I) collagen chain have
been described in osteogenesis imperfecta type
II, indicating that mutations in this region can
have a dramatic eVect on the function of a
fibrillar collagen molecule.27
In patient R91-68, a 4 bp deletion was found
at the donor splice site of intron 35. Although
the possibility of exon skipping could not be
investigated at the cDNA level, the overmodifi-
cation of the type II collagen CB peptides (fig
2A) indicates that an abnormal á1(II) chain
was expressed and incorporated into the
matrix. We concluded that the mutation pro-
bably resulted in skipping of exon 35 with shor-
tened chains being incorporated into the tissue
fabric. Consistent with the published findings
of others, the phenotype of this case was
considerably milder than that of the three cases
with a glycine substitution.2 It is notable that
most cases of Kniest dysplasia, which is usually
a non-lethal type II collagen disorder, are
caused by COL2A1 exon skipping
mutations.28–31 These deletions tend to be con-
centrated in the amino-terminal half of the
molecule. Since the type II procollagen mo-
lecule consists of three identical á1(II) chains,
heterozygosity for a missense mutation in the
COL2A1 gene should result in seven/eight pro-
collagen trimers containing one, two, or three
mutated á1(II) chains. A mutation in one
COL2A1 allele aVecting mRNA splicing and
resulting in an in frame deletion of several
amino acids will give rise to six/eight procolla-
gen trimers containing a mixture of normal and
deletion containing chains. Two/eight of the
molecules will contain either three normal or
three shortened á1(II) chains. This could
explain to some extent the diVerence in pheno-
typic outcome between glycine substitutions
and in frame deletions as a result of aberrant
splicing. However, not all glycine substitutions
in the á1(II) chain result in a severe phenotype
as they can also cause milder cases of SEDC
and phenotypically milder spondyloepimeta-
physeal dysplasia Strudwick type.2 32 The
phenotype probably depends not only on the
mutation type (for example, exon deletion or
glycine substitution), but also on the local
domain of the triple helix aVected.
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Letters to the Editor
J Med Genet 2000;37:785–787
The mutation spectrum in Holt-Oram
syndrome
EDITOR—Holt-Oram syndrome (HOS) is a developmental
disorder characterised by malformations of the radial ray of
the forelimb and by congenital heart disease.1 The
syndrome shows a marked variability in phenotype, with
radial ray defects ranging from minor thumb abnormality
through to severe reduction defect or phocomelia. The
cardiac manifestations of HOS are similarly varied, and
patients can present with a variety of structural heart
abnormalities, atrial septal defects (ASDs) and ventricular
septal defects (VSDs) being the most common, or conduc-
tion defects evident on ECG profiles. Previous studies have
shown no correlation between the severity of a patient’s
cardiac and skeletal abnormalities.2 Intrafamilial variation
can be wide.
HOS shows autosomal dominant inheritance and muta-
tions in the T box transcription factor gene (TBX5) have
been shown previously to be responsible for this disorder.3 4
There is also evidence for genetic heterogeneity.5 The
mechanism by which mutations in TBX5 cause a dominant
phenotype is not understood at present, and it is
anticipated that knowledge of the type of mutations
causing HOS may shed light on this. Knowledge of a large
number of mutations and the relation of a person’s
genotype to phenotype is also useful for genetic counsel-
ling. In the face of a growing demand for a molecular diag-
nostic test for HOS, it is also helpful to have a quantitative
estimate of the ability of current methods to detect muta-
tions in TBX5.
Twenty five cases with a clinical diagnosis of Holt-Oram
syndrome have been tested for this study, bringing to 47
the total number of cases studied by us. Minimal diagnos-
tic criteria were as described previously2: bilateral radial ray
defect, plus either cardiac abnormality or family history of
cardiac abnormality. Cases were referred by a variety of
clinicians and underwent full clinical assessment including
x ray, electrocardiography (ECG), and echocardiography.
Information regarding the clinical features of these patients
came from the referring doctor. The patients represented
both sporadic (8) and familial (17) cases of Holt-Oram
syndrome.
Mutational analysis was carried out using SSCP
methods initially, followed by fluorescence sequencing of
exons showing a non-standard SSCP banding pattern. The
methods used were described in Li et al.3 Since that study,
further analysis of the genomic structure of TBX5 has rec-
ognised that the previously reported exon B is in fact two
exons. Extensive resequencing of both genomic and cDNA
forms of TBX5 has also been undertaken, leading to revi-
sions in the previously reported TBX5 sequence (the new
sequence has accession number AF221714). This se-
quence is the same across the coding region as that
produced by others.6 Of 17 new familial cases tested, eight
showed linkage to chromosome 12 and the other families
were too small to assess linkage. Table 1 shows that five
mutations were identified in familial cases. Only one of
these families was suYciently large to show meaningful
linkage to chromosome 12q markers. Of eight new
sporadic cases studied, three have yielded mutations. Thus,
in the 34 familial cases studied by us, eight mutations have
been identified, and six mutations have been identified in
13 sporadic cases. The precise natures of all the new muta-
tions identified are detailed in table 2.
The clinical features of HOS in all 47 cases are consist-
ent with the previously described phenotype2 and show the
wide spectrum of cardiac and skeletal abnormalities in this
syndrome (see Bruneau et al7 for details of the complexity
of cardiac abnormalities in HOS patients). Most patients
show at least one defect of cardiac septation (an atrial or
ventricular septal defect, or atrioventricular block) and
abnormalities of the thumb. Radial hypoplasias and
aplasias are present in sporadic cases PpHs, H20s, H22s,
and H16s and in the familial cases H6f and Ghf, although
not in every aVected member.
Twenty five non-translocation mutations have been
reported, including those presented here. These mutations
are of 19 distinct types, with six mutations being identical to
previously described forms identified in unrelated subjects
(this paper and Basson et al6). Of the 19 distinct
non-translocation, disease causing mutations in TBX5 cur-
rently known, five are truncations, five amino acid substitu-
tions, three splice site changes, and six reading frame shifts.
We have observed a significant diVerence in the
proportion of cases in which a mutation was detected in our
group of sporadic cases as opposed to our group of familial
cases. Forty six percent (6/13) of sporadic cases studied in
our laboratory have yielded mutations by SSCP screening,
whereas only 24% (8/34) of familial cases have done so.
The overall mutation detection rate of 30% may be low
for a variety of reasons. An inadequate mutation detection
method would explain these results, yet the system in use
by us is a standard one used on a variety of projects, all of
which produce detection rates nearer the theoretical level
for these techniques (approximately 95%). The largest
PCR product used in the present analysis is only 326 bp
long, well within the size acceptable for this kind of analy-
sis. Mutation detection is also fully repeatable in our hands.
There are four other possible explanations for this low
mutation detection rate: (1) clinical misdiagnosis in our
patients, (2) genetic heterogeneity of Holt-Oram
syndrome,5 (3) the presence of mutations in the untrans-
lated and promoter regions of TBX5, which have not been
tested in this analysis, and (4) deletion of whole exons of
TBX5, which would not be recognised by SSCP.
Table 1 Cases studied
This study All studies in our lab
Familial cases studied 17 34
Sporadic cases studied 8 13
Mutations found in familial cases 5 8
Mutations found in sporadic cases 3 6
Table 2 New mutations identified
Case Mutation type Location Mutation form Result
Nef Substitution Intron 4–5 5' splice site(T to C) Splice site change
FIf Substitution Exon 5 nt1170(G to A) Gly to Arg
FR9f Substitution Exon 8 nt1611(G to T) Stop codon TAG
Jonf Substitution Exon 6 nt1233(G to T) Stop codon TAA
Chas Substitution Exon 7 nt1420(G to T) Ser to Ile
Bers Deletion Exon 8 nt1470(del T) Reading frameshift
PpHs Substitution Exon 8 nt1500(C to T) Stop codon TGA
GHf Substitution Exon 8 nt1500(C to T) Stop codon TGA
Codes ending in f are familial cases, those with s are sporadic.
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Other studies of HOS have not published mutation
detection rates. We can only speculate as to why the rate of
mutation detection in sporadic cases should be higher than
that in familial cases (particularly in those familial cases
whose disease loci are known to be present on 12q). An
obvious explanation for such a discrepancy is ascertain-
ment bias. A sporadic case must have both detectable heart
and limb symptoms to be diagnosed as having HOS,
whereas a family need only show both these eVects across
the pedigree (rather than in one subject) along with an
autosomal dominant inheritance pattern.
A group of five of the 25 mutations published so far are
the same, a C to T transition at position 1500, generating a
stop codon. This mutation is seen in both sporadic and
familial HOS cases among patients who do not share com-
mon alleles at microsatellite loci closely linked to TBX5.
This site is likely to represent, therefore, a true “mutation
hotspot”. The residue is part of a CG duplet, and therefore
is likely to be methylated, with a high frequency of
mutation to a thymine residue. Studies across a variety of
human diseases have found distributions of mutations
skewed towards the mutation of CpG sites. The retino-
blastoma gene, RB1, shows a distribution of mutations
severely skewed towards a few C→T transition hotspots
(see the RB1 mutation database8 for details).
Basson et al6 argue, based on a collection of HOS fami-
lies of varying symptom severity, that there is a relationship
between the phenotype of patients and their specific muta-
tion. It is proposed that truncation mutations in TBX5 lead
to both limb and cardiac malformation, whereas single
amino acid changes have diVerent eVects depending on
their position in the T box. The set of HOS cases we have
examined contains no large families of the type studied in
this earlier analysis.
The five known cases (two familial and three sporadic)
with the same mutation, a C→T transition at nucleotide
1500 in exon 8, present an opportunity to examine more
closely the possibility of mutation specific genotype-
phenotype correlation in cases with a truncation in TBX5.
The clinical phenotypes of these cases are presented in
table 3. Cardiac defects presented include isolated ASD
and isolated VSD but no case with this mutation has a
complex cardiac lesion. Syndactyly of the thumb and first
finger is common within this group. There is much
variation in symptom severity and the group as a whole
shows no bias towards a particular severity of either cardiac
or skeletal symptoms, in agreement with Basson et al.6
Along with the truncation forms already described, we
have identified two new mutations which each result in a
single amino acid substitution. The change in family Fif
inserts an arginine in place of a glycine at position 169,
which is conserved across T box genes such as Xbra (Xeno-
pus), T (mouse), TbxT (chick), and omb (Drosophila).9 This
introduces a strongly basic residue into a non-polar region
in the DNA binding T domain. Family Fif comprises eight
aVected subjects in two generations, who show significant
cardiac involvement compared with very mild skeletal
findings. One case has a complex lesion, ASD with VSD,
and another case has pulmonary stenosis, a conotruncal
malformation which is not typical in HOS. This is consist-
ent with a role for TBX5 which extends beyond cardiac
septation.10 Only one subject in family Fif has a
demonstrable limb abnormality and this is stiVening of the
thumbs. The phenotype of this family is therefore consist-
ent with the suggestion that substitution mutations
produce predominantly limb or predominantly cardiac
features, depending upon their location within TBX5.6
The change of a serine to an isoleucine in patient Chas
is outside the T domain of the protein and its biochemical
eVects are not known. The phenotype of this patient
included a spinal scoliosis, which has not previously been
observed in Holt-Oram syndrome, together with bilateral
hypoplastic thumbs, syndactyly, and a ventricular septal
defect. Currently available details on expression of TBX5
during development of the mouse and chick give no
evidence of expression in the developing spine which would
account for such a phenotype being the result of mutation
of TBX5.12 13
In summary, these new data expand our knowledge of
the spectrum of mutations that cause Holt-Oram syn-
drome and also raise interesting questions about the
genetic heterogeneity of this disease and its mutations.
Clearly there is a need to improve the frequency of muta-
tion detection in HOS and current analysis of untranslated
and promoter regions, and screens for whole exon
deletions should prove useful. A diagnostic service for
TBX5 mutations is being set up.13
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Table 3 Clinical phenotypes
Family Pedigree No Mutation Skeletal abnormality Cardiac abnormality
H8f I.1 Exon 8 Bilateral hypoplastic thumbs AV block
nt1500 C→T Syndactyly 1/2
II.2 Right triphalangeal thumb ASD
Left absent thumb
Bilateral radial hypoplasia
H12f I.1 Exon 8 Bilateral hypoplastic thumbs AV block
nt1500 C→T Syndactyly 1/2
II.1 Bilateral hypoplastic thumbs AV block
Syndactyly 1/2
II.3 Absent thumbs VSD
Bilateral radial hypoplasia
H22s Exon 8 Bilateral triphalangeal thumbs ASD
nt1500 C→T Bilateral radial hypoplasia
PpHs Exon 8 Bilateral absent thumbs AV block
nt1500 C→T Left radial aplasia
Right radial hypoplasia
Ghf Exon 8 Bilateral absent thumbs ASD
nt1500 C→T Right radial aplasia
Left radial hypoplasia
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Hemiplegic cerebral palsy and the
factor V Leiden mutation
EDITOR—Two mutations have been identified in recent
years that predispose a heterozygous carrier to venous
thrombosis. One is a mutation localised to the factor V
gene, Arg 506 to Gln (factor V Leiden mutation, FVL),
which has been shown to be the most common cause of
familial thrombosis1 2 through resistance to activated
protein C (APC), which is an inhibitor of activated factors
V and VIII.3 The second is in the gene for the coagulation
factor prothrombin (factor II), the G20210A mutation.4
There are two published estimates of prevalence of the
FVL mutation in the Australian population, the first in a
study of recurrent miscarriage,5 where 3.5% of the controls
had FVL. The other is a recent study of blood donors
where 3.6% were found to be heterozygous.6
Fewer studies have been done on the prothrombin (PT)
mutation which is not as prevalent, thought to occur in
approximately 2% of healthy, normal controls.1 4
Of particular relevance to this study are the findings of
children with ischaemic strokes7–9 or thromboembolism,10 11
who have been reported as having a high prevalence of the
FVL mutation. A more recent study12 suggests that neither
FVL nor PT is a risk factor for childhood stroke and that “a
large prospective multicentre study is required” to investi-
gate this further. There has also been a report of three babies
with hemiplegic cerebral palsy (CP) who were heterozygous
for the FVL mutation.13 In the three cases, there was a sug-
gestion that placental infarction/thrombosis or neonatal
stroke may have occurred and resulted in the hemiplegia.
Other relevant studies have also been done, suggesting that
placental infarction and late fetal loss14 15 may occur more
frequently in women who are carriers of FVL.
Cerebral palsy (CP) is a common physical disability in
childhood occurring in 2.0-2.5 per 1000 live births. In a sig-
nificant proportion, no cause can be established. Current
research suggests that between 6 and 8% of cases are the
result of birth asphyxia16–18 and postnatal problems account
for a further 10%.19 20 Prenatal events are now thought to be
responsible for approximately 75% of all cases of cerebral
palsy, although it is usually impossible to determine the
nature and exact timing of the damaging event. Given the
lifetime impact that cerebral palsy has on the person and the
family, a search for further causative factors is essential, as
new information regarding aetiology may provide the first
step to instituting preventive strategies.
In Victoria, there is a CP Register containing demo-
graphic and clinical details of 2093 babies born between
1970 and 1995. A letter was sent to the parents of 69
selected patients requesting permission to access the blood
spot collected routinely at birth (Guthrie card) for
newborn screening purposes. These 69 were chosen
because they were private patients of one of the authors
(DR) and could therefore be approached directly. The
identifiable blood spots are held at The Murdoch
Children’s Research Institute and are not available for
research or other purposes unless permission is obtained
from the parents. All had a diagnosis of cerebral palsy with
a specific motor diagnosis of spastic hemiplegia.
We estimated that a sample size of 50 would detect a sig-
nificant increase in prevalence of the FVL mutation from a
background prevalence of 4% to one of 15%, with a power
of 80% and alpha of 0.05.
Two 3 mm2 sections of Guthrie blood spots were cut out
and placed in 50 µl of PCR buVer. They were initially
incubated at 95°C for 30 minutes, then kept at 37°C over-
night, after which they were pulse centrifuged. The super-
natant was then transferred to a sterile 500 µl tube and kept
at 4°C until the day of analysis.
DNA encompassing the FVL codon 506 mutation was
amplified by PCR. The resulting product was checked on
a 1% agarose gel stained with ethidium bromide before
restriction enzyme digestion. DNA was digested overnight
at 37°C using the enzyme MnlI. Fragments were then
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separated on a 6% polyacrylamide gel and subsequently
stained with ethidium bromide. Both normal and heterozy-
gote samples were run as controls in each assay.
The same methodology was applied for detection of the
prothrombin 20 210 polymorphism, but with HindIII
restriction enzyme used, and with digest fragments being
separated on a 3% agarose gel.
Power calculations were done in SPSS for Windows,
version 8.0, SAMPLE POWER, and the binomial
comparison of the sample prevalence with the estimated
population prevalence was also done in SPSS version 8.0.
Of the 69 parents contacted, 58 responded (84%). All
gave permission for use of the blood spot, except for one
where the child was in the care of foster parents who did not
feel that it was appropriate to give consent. Two Guthrie
cards were unable to be found leaving a sample of 55 cases.
Of the 55 subjects recruited, 54 and 52 could be ampli-
fied successfully for the FVL and PT mutations, respec-
tively. Of the 54 samples screened for FVL, one was found
to be homozygous while three were found to be
heterozygous. Therefore, the frequency of cases with at
least one mutation of FVL was 7.4% which does not diVer
significantly from the average Australian population
heterozygote prevalence of 3.6% (binomial test, one tailed
p value=0.13). Only one of the 52 samples analysed for PT
was found to be heterozygous (1.9%).
The clinical features of the five subjects with positive
findings are as follows.
(1) Homozygous for FVL mutation. This child was born
by caesarean section at 32 weeks following a pregnancy
complicated by pre-eclamptic toxaemia. His birth weight
was 1815 g. Hemiplegic cerebral palsy was diagnosed at the
age of 4 months. A CT brain scan showed appearances con-
sistent with infarction. There was no family history of note
but testing showed that his mother is a heterozygote for FVL.
(2) Heterozygous for FVL mutation. These three children
were all normal birth weight, term infants. One child
required some resuscitation at birth and meconium had
been passed before delivery. Her MRI showed middle and
anterior cerebral atrophy infarction. The family history was
unremarkable apart from the unexpected death of the pater-
nal grandfather, from a myocardial infarct, at 50 years of age.
The other two children had uneventful perinatal periods and
hemiplegia became apparent during the first year of life.
Both had CT scans which showed loss of cerebral
hemisphere substance in both grey and white matter with
enlarged ventricles, not necessarily typical of major vessel
infarction. While one child had a negative family history, the
other child’s grandmother had sustained a deep venous
thrombosis following a hysterectomy at the age of 50 years.
(3) Heterozygous for the prothrombin mutation. This
child had an uneventful perinatal period. A diagnosis of
hemiplegic cerebral palsy was made at the age of 8 months.
A CT brain scan showed signs of infarction with almost
complete absence of the left frontal temporal and parietal
lobes, with appearances typical of congenital occlusion of the
left anterior and middle cerebral arteries and subsequent
porencephaly. There was no family history of note.
All available radiological findings were assessed and are
summarised in table 1.
If only cases with radiological evidence of ischaemia (14
cases) are used in the calculations, the frequency of either
of the thrombophilia mutations (three cases) is 21%. This
is significantly higher than the population prevalence
(binomial test, one tailed p value=0.013).
In summary, evidence of the influence of the FVL muta-
tion on thrombosis led us to consider whether a significant
attributable factor to CP may be the presence of this muta-
tion, which could cause an adverse vascular event such as
placental infarcts or stroke in utero or early in postnatal
life. To test this hypothesis, we obtained the frequency of
the mutation in blood spots from a sample of children, all
of whom had hemiplegic CP. This group was chosen
because it was thought to be relatively homogeneous and it
seemed that if a vascular event were causative, then spastic
hemiplegia could be the most likely outcome. However, an
examination of their radiological findings, after the
mutation detection had been undertaken, showed quite
marked heterogeneity. It was among the 14 cases with a
known ischaemic event that three mutations were found,
giving a significantly higher prevalence of 21%.
From these results, we conclude that there may be a rela-
tionship between carrier status for mutations predisposing
an infant to thrombophilia and cerebral vascular events in
utero (or neonatally) that lead to CP. To confirm such a
relationship it will be necessary to study a larger sample of
CP patients with a vascular basis, such as venous or arterial
occlusion, and compare mutation frequencies with children
with CP who do not have a vascular basis for CP.
In addition, investigation of maternal mutation status
would be useful, particularly because the frequency of
maternal pre-eclampsia in this sample was higher than
expected (data not shown), 11% compared with the
reported population frequency of approximately 5%21 22 and
it is not known whether these mothers had FVL or PT
mutations.
We report our findings at this stage to illustrate how
DNA testing for common polymorphisms, which are of
unknown importance in the general population, may be of
importance to subjects within subgroups of the population.
Primarily this would be for clinical management, but per-
haps when potentially interactive aetiological factors, such
as smoking in pregnancy, are better defined, this genetic
information could be used for preventive measures.
We would like to thank Nick Tzanakos in the newborn screening laboratory of
the Victorian Clinical Genetics Service, Murdoch Institute, for his technical
assistance and Carole Webley for help in preparation of the manuscript.
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Table 1 Radiological findings
Radiology Normal
Evidence of
ischaemic lesion Hydrocephalus PFVL IVH
Non-specific
lesion Total
Ultrasound 3 — 3 1 2 1 10
CT scan 1 10 (2) 2 1 — 3 (2) 17
MRI — 4 (1) 1 1 — — 6
Not available/not done 22
Number in brackets refers to number of patients with mutation.
PFVL: periventricular leucomalacia.
IVH: intraventricular haemorrhage.
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Analysis of the human tumour necrosis
factor-alpha (TNFá) gene promoter
polymorphisms in children with bone
cancer
EDITOR—TNFá (tumour necrosis factor-alpha) is a cytokine
produced by macrophages and monocytes with a wide range
of activities, and polymorphisms within this gene have been
postulated to contribute to MHC associations with autoim-
mune and infectious diseases.1 The role of TNFá in cancer
is a controversial matter, because while it plays a key role in
the “in vitro” killing of tumour cells by macrophages and
lymphocytes, it has also been found in high concentrations in
patients with cancer, suggesting that it may be an
endogenous tumour promoter “in vivo”.2 3 DiVerent results
with several tumour types show that TNFá may have both
tumour necrotic and tumour promoting activities.
Recently, several genetic polymorphisms have been
described in the human TNFá promoter.4–6 Among them,
the rare allele at position −308 (TNF308.2) has been
proven to be part of a complex haplotype that is involved in
higher TNFá levels and has been related to poor prognosis
in several diseases.7 The existence of diVerent TNFá
alleles, related to diVerent levels of TNFá, raises the possi-
bility that tumour development is somewhat related to the
genetic propensity of the person to produce higher levels of
TNFá and, therefore, with the presence of genetic variants
in this gene. In fact, an increase in the TNF308.1/
TNF308.2 genotype has been reported in diVerent tumour
types, with a significantly increased frequency of the
TNF308.2 allele in patients with malignant tumours.8
Wilson et al7 have shown that the polymorphism at −308
has a significant eVect on the transcriptional activity of the
human TNFá gene, either because the interaction of the
transcription enhancers is increased owing to the diVerent
DNA conformations, or because the TNF2 variant is the
target for novel binding proteins.
The G to A transition at position –238 (TNF238.2) is
also suspected to influence the expression of TNFá, and
although its clinical and functional consequences are not
clear so far,9 it has been associated with development and
prognosis of diVerent diseases as well.10 11
The eVects of TNFá on osteoblast diVerentiation and
proliferation are complex but it is generally assumed that it
inhibits bone formation and stimulates bone resorption.12
The activity of TNFá in osteosarcoma, Ewing’s sarcoma,
and primary human osteoblast cultures has been widely
studied showing that it has an antiproliferative and
cytotoxic role which usually depends on the type of cell line
under analysis.13 14
Synergistic cytotoxicity has been described between
TNFá and other cytokines, most frequently IFNã
(interferon gamma) and also with certain drugs that are
commonly used in the treatment of osteosarcoma and
Ewing’s sarcoma like the topoisomerase II inhibitors.13 The
data available indicate that TNFá and agents that stimulate
its production by host macrophages may have a role in the
treatment of osteosarcoma and Ewing’s sarcoma.
Based on the role of TNFá in bone biology and the
growing evidence of the relationship existing between
TNFá genetics and cancer, we tried to test the hypothesis
of whether genetic polymorphisms of the TNFá promoter
contribute to the pathogenesis or prognosis of paediatric
bone tumours.
DNA was extracted following standard procedures15
from peripheral blood lymphocytes of 110 paediatric
patients (52 females, 58 males) with bone tumours (63
osteosarcomas and 47 Ewing’s sarcomas) and 111 healthy
children (53 females, 58 males). All the subjects included
in the analysis were white, most of them from the region of
Navarre (Spain), and the age distribution was very similar
in the tumour and control groups (mean (SD): osteo-
sarcoma 13.5 years (SD 3.3), Ewing’s sarcoma 12 years
(SD 3.7), controls 11.1 years (SD 5.1)).
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The human TNFá promoter region between nucleotides
−398 and −103 was analysed by PCR-DGGE (polymerase
chain reaction coupled to denaturing gradient gel electro-
phoresis) as previously published16 17 (fig 1).
Statistical analyses were performed with the Statistical
Package for the Social Sciences (SPSS, version 9.0). The
chi-square contingency test, with Yates’s modification for
small numbers if needed, was used to test for a significant
association between disease and TNFá genotypes or
haplotypes. Crude odds ratios (ORs) were calculated and
given with 95% confidence intervals (CI). To test for
association between clinical parameters and genotypes or
haplotypes, t tests or one way analysis of variance
(ANOVA) were performed. Statistical significance was
assumed if p<0.05 and highly statistical diVerence if
p<0.01; diVerences between variables with p>0.05 were
considered not statistically diVerent. Osteosarcomas and
Ewing’s sarcomas were treated independently in the statis-
tical analyses given that they are diVerent clinical entities,
both in genetic background and in the clinical and
histological aspects.
We have analysed the distribution of the TNFá gene
promoter polymorphisms at positions –376, −308, −238,
and –163 in 110 bone sarcoma paediatric patients and in
111 paired healthy children, to search for the putative
association between the TNFá gene and tumour develop-
ment or prognosis.
The overall distribution of TNFá polymorphic alleles in
bone cancer paediatric patients and control subjects is
shown in table 1. As in previous reports, polymorphisms at
−376 and −238 were found to be in linkage
disequilibrium.5 To date, there are no consistent data on
the frequency of the polymorphic alleles at –376 and –163
in white populations, and larger series should be screened
to establish the frequencies for these alleles in both normal
and disease related populations.
The frequencies of the alleles at −308 and –238 in the
Spanish population (0.87 and 0.92, respectively, deduced
from table 2) were found to be very similar to those
described for European white populations.10 18
Tables 2 and 3 show the allele and genotype frequencies
of the genetic variants of the TNFá gene promoter at –308
and –238 in both cancer patients and healthy subjects. The
frequency of the TNF238.2 allele (adenine at position
–238) and TNF238.1/TNF238.2 heterozygote genotype
was significantly lower in the osteosarcoma group, but not
among Ewing’s sarcomas. We did not find any outstanding
diVerence in the distribution of the TNF308.2 allele
(adenine at position –308) between bone sarcomas and
controls.
No relationship was found between the presence of
genotypes for the TNFá gene promoter and any of the
clinical parameters tested: tumour stage, tumour location
or size, development of metastasis or relapse, and age at
diagnosis (data not shown).
Surprisingly, the percentage of males carrying polymor-
phisms of the TNFá promoter was statistically higher than
in females (p=0.025, OR=4.05, CI=1.13-14.43). We did
not detect this diVerence in the group of healthy controls,
in which the distribution of polymorphic patterns was
similar in both sexes.
Several reports have indicated that diVerent HLA
(human leucocyte antigen) products and related genes may
be risk factors for and also protective factors against
cancer. The TNFá gene is of particular interest because of
its involvement in tumour immunity and cancer pathogene-
sis and the relationship existing between certain TNFá
genetic variants and human tumours.
Although the exact regulatory mechanisms altered by
the TNFá promoter polymorphisms are not completely
delineated, studies on these polymorphisms have shown
that those at −308 and −238 are associated with the devel-
opment and even prognosis of certain types of cancer.
Chouchane et al8 detected a marked decrease of the
TNF308.1 homozygous genotype in patients with non-
Hodgkin’s lymphoma, breast carcinoma, and in a group of
diVerent malignant tumours. Nevertheless, it must be taken
into account that the results of this study were obtained with
Figure 1 DGGE gel showing polymorphic and normal
band patterns. Lanes 1 to 3: genotype normal/−376−238.
Lane 4: genotype normal/−308. Lanes 5 and 6: normal,
non-polymorphic patterns.
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Table 1 Genotypes for the TNFá gene promoter in the control subjects
and the bone tumour groups
Genotypes
Controls (n=111)* Osteosarcoma (n=63) ES† (n=47)
No % No % No %
Normal/normal 67 60.4 47 74.6 35 74.5
Normal/−308 26 23.4 13 20.6 6 12.8
Normal/−238−376 11 9.9 2 3.2 4 8.5
−308/−238−376 2 1.8 0 0 0 0
Normal/−238 5 4.5 0 0 2 4.3
−308/−308 0 0 1 1.6 0 0
*Number of subjects analysed.
†ES, Ewing’s sarcoma.
Table 2 Frequencies of the TNFá promoter alleles –238 and –308 in the paediatric bone sarcoma groups compared to
control children
Allele
Controls (n=222)* Osteosarcoma (n=126) ES† (n=94)
No % No % No %
Locus TNFá -308
G (TNF308.1) 194 87.4 111 88.1 88 93.6
A (TNF308.2) 28 12.6 15 11.9 6 6.4
p=0.847, NS, OR=0.94 (CI 0.48, 1.83) p=0.102, NS, OR=0.47 (CI 0.19, 1.18)
Locus TNFá -238
G (TNF238.1) 204 91.9 124 98.4 88 93.6
A (TNF238.2) 18 8.1 2 1.6 6 6.4
p=0.012, ‡, OR=0.18 (CI 0.042, 0.8) p=0.6, NS, OR=0.77 (CI 0.29, 2.01)
*Number of alleles analysed.
†ES, Ewing’s sarcoma.
‡Statistically significant.
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adult patients in the Tunisian population and the polymor-
phisms of TNFá are dependent on ethnicity.
In the present study, we report a decrease in the
TNF238.2 rare allele among osteosarcoma paediatric
patients and no diVerence from the control population in
the distribution of the TNF308.2 variant in either of the
tumour groups analysed, while other authors have
described a decreased representation of the TNF308.2
allele in cancer populations (for example, in chronic
lymphocytic leukaemia).19
Although the exact influence of the TNF238.2 variant
on TNFá function and expression is not fully understood
to date, the localisation of this polymorphism in the regu-
latory Y box20 suggests that it may contribute to the optimal
function and regulation of the TNFá promoter. However, it
has been proven, in transfection assays, that there are no
diVerences in TNFá production after stimulation of
TNF238.2 heterozygous or normal homozygous cells;
therefore TNF238.2 is not likely to be of functional
relevance for transcriptional activation, and the actual
meaning of the –238 promoter polymorphism remains a
controversial matter.
There is evidence that the −308 TNF2 allele is over-
expressed in diseases where TNFá levels are associated with
poor prognosis. In our bone sarcoma series, we did not find
a relationship between this or any other polymorphic variant
of the TNFá promoter and tumour prognosis, disease free
survival or development of metastasis or relapse (data not
shown). One hypothesis is that these polymorphisms may
serve as markers for additional polymorphisms or mutations
in neighbouring genes that may be involved in the disease.
With regard to the increased number of TNFá polymor-
phic alleles in male osteosarcoma patients, several other
authors have reported gender diVerences and increased
TNFá levels in male patients aVected by type II diabetes
mellitus.21 A possible explanation for this finding is that the
increased plasma levels of TNFá in males are the
consequence of the presence of an increased number of the
TNF308.2 allele, which has been associated with higher
expression of the TNFá gene. In fact, in our series of
osteosarcoma, there is a tendency for a higher number of
TNF308.2 alleles in male patients, without reaching, how-
ever, statistical significance (p=0.079).
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Low prevalence of germline BRCA1
mutations in early onset breast cancer
without a family history
EDITOR— Germline mutations in the BRCA1 and BRCA2
genes cause predisposition to breast and ovarian cancer.1
Epidemiological evidence and linkage studies suggested
that the likelihood that a woman with breast cancer has a
genetic susceptibility to the condition is greater the
younger she was at diagnosis and with increasing extent of
family history of the disease. Studies of the prevalence of
germline mutations in BRCA1 and BRCA2 in women with
breast cancer has enabled the frequency of mutations to be
determined in women with diVerent ages at diagnosis and
extent of family history of breast cancer.2 3 The CASH
study into the attributable risk of breast and ovarian cancer
estimated that 33% of all breast cancers diagnosed by the
age of 29 years, and 22% diagnosed by the age of 30-39
years, are the result of an inherited mutation.4 However,
the proportion of breast cancer cases diagnosed by 40 years
resulting from a BRCA1 mutation was predicted to be
5.3%.5 Previous population based studies of the prevalence
of BRCA1 mutations in early onset breast cancer have been
in cases unselected for family history, and the majority of
mutation carriers detected did have some degree of family
history of either breast or ovarian cancer.6–10 The aim of this
study was to establish the prevalence of BRCA1 mutations
in a large series of British patients with a young age of onset
and no known family history of the disease, since such
patients are referred relatively frequently for genetic coun-
selling. The presence of BRCA1 mutations in a significant
proportion of these patients would have important
implications for the planning of a mutation screening strat-
egy in diagnostic services.
Patients were ascertained from the Imperial Cancer
Research Fund Clinical Breast Oncology Department at
Guy’s Hospital, and the family cancer clinics at the Genet-
ics Departments of Guy’s Hospital and the Royal Free
Hospital, both in London, and from St Mary’s Hospital,
Manchester. The Manchester cases were initially ascer-
tained as part of a population based series for other studies.
Patients without a known family history of breast or ovar-
ian cancer at referral were recruited into this study, and
these patients were interviewed at home by a genetic nurse
counsellor. A family history was taken by the clinical
geneticist or genetic nurse counsellor, and the diagnosis
confirmed in all probands with either the referring breast
unit or the patient’s GP or oncologist. Patients with a
known family history of breast or ovarian cancer at referral
were excluded from the study. The range of age of diagno-
sis was 22-35 years and the median age of diagnosis was 31
years. Blood samples were taken after the purpose of the
study had been explained and informed consent obtained.
Full genetic counselling was provided, following agreed
protocols, and results were made available to those women
wishing to be informed.
The 22 BRCA1 coding exons were amplified using 24
pairs of primers (exon 11 was amplified in three
overlapping fragments). The fluorescent chemical cleavage
of mismatch (FCCM) protocol was adapted from the
method of Rowley et al.11 PCR products were labelled by
incorporation of dUTP analogues which were labelled with
either R110 (blue), R6G (green), or Tamra (yellow)
fluorescent dyes (PE Applied Biosystems Inc), and
heteroduplex molecules then subjected to hydroxylamine
modification and piperidine cleavage. Using the three dif-
ferent dyes to label the 24 PCR products that cover the
complete BRCA1 coding sequence, three patients could be
analysed for one fragment in one lane of the gel; thus three
patients were completely screened in 24 lanes and six
patients were screened on a 50 well gel. The FCCM tech-
nique has been reported to detect over 95% of mutations in
a blind study of haemophilia A patients.11 We evaluated the
sensitivity of our BRCA1 protocol by examination of the
eight polymorphisms that have been reported in the
BRCA1 gene with a frequency of at least 5% (1186A/G,
2201C/T, 2430T/C, 2731C/T, 3232A/G, 3667A/G,
4427C/T, 4956A/G).12 These polymorphisms were all
detected reproducibly at the expected frequency in a panel
of over 400 patients who were tested, as part of our
continuing studies. In addition, FCCM detected the
mutations in three known BRCA1 positive samples (188del
11bp, 5242 C/A, and 5382insC) that were previously
found in our laboratory by SSCP analysis.13 The
fluorescent chemical cleavage assay which we have
developed therefore allows a rapid and sensitive mutation
screen of BRCA1.
Four mutations that were likely to be pathogenic were
detected in 110 patients (3.6%) and are listed in table 1.
These included three sequence variants that would be pre-
dicted to result in premature termination of translation.
The 185delAG frameshift mutation, which is prevalent in
the Ashkenazi Jewish population, was identified in a British
patient (91032) with Jewish ancestry. The 4693-
4694delAA mutation was detected in a British patient
(78750) who was diagnosed with breast cancer at the age of
26 years. The truncating mutation 3875-3878delGTCT
was seen in a patient of Afro-Caribbean origin (94641),
who was diagnosed with breast cancer aged 33 years and
with a second primary cancer at 38 years. Testing for this
mutation in the parents of the patient indicated that it was
inherited from her father. A novel in frame deletion, 1965-
1967delTCT, was detected in a patient of West African
origin (103727) who was diagnosed with breast cancer at
the age of 27 years. This mutation would be predicted to
result in the deletion of a single amino acid, serine 616, but
would not lead to premature termination of translation.
This sequence change was absent in over 350 control
chromosomes in our study and fulfils all the other criteria
for pathogenic status.13 The pedigrees of these four women
are shown in fig 1. Although all four patients originally
reported no family history of breast cancer, further investi-
gation showed that the maternal great grandmother of
patient 103727 was diagnosed with the disease at about 60
years of age. The lack of a history of breast or ovarian can-
cer in these families is likely to result from a combination of
factors including paternal transmission of the mutation,
chance, and reduced penetrance.
Eight other rare DNA sequence variants were identified
(table 2). Three of these would not be predicted to alter the
expression of BRCA1 or the sequence of its encoded pro-
tein (Q1604Q, IVS22+8T/C, UGA+36T/C) and R1347G
Table 1 BRCA1 pathogenic mutations
Patient Exon Nucleotide change Amino acid change
91032 2 185-186delAG 39 stop
103727 11 1965-1967delTCT S616del
94641 11 3875-3878delGTCT 1264 stop
78750 15 4693-4694delAA 1529 stop
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was present in a patient with a frameshift mutation.12 The
pathogenic status of the other four (Q804H, S1140G,
P1637L, and M1652I) remains inconclusive in the absence
of a functional assay for the BRCA1 protein. At present,
screening panels of ethnically matched controls is a useful
means of excluding missense mutations as pathogenic
mutations of high penetrance, and it would be helpful if
this information was provided in the Breast Cancer
database (www.nhgri.nih.gov/Intramural_research/
Lab_transfer/Bic/index.html).
Our detection of pathogenic BRCA1 mutations in 3.6%
of young breast cancer patients without a family history of
breast or ovarian cancer is consistent with the estimate of
Ford et al5 that the proportion of breast cancer cases in the
general population resulting from BRCA1 is 5.3% below
the age of 40 years. A recent population based study of
young British breast cancer patients unselected for family
history found BRCA1 mutations in nine of 254 (3.5%)
women diagnosed by the age of 36 years.8 In North Ameri-
can studies of BRCA1 mutations in women unselected for
family history and diagnosed below the age of 35 years,
Langston et al7 detected mutations in 7.5%, Malone et al9 in
6.2%, and Struewing et al10 in 5.7%. Fitzgerald et al6
detected BRCA1 mutations in 13% of women diagnosed
before the age of 30 years, but this included Ashkenazi
Jewish patients who have founder mutations and some
patients with a family history. Since we did not screen the
promoter region of BRCA1 or for deletions of entire
exons,14 we cannot exclude the possibility that some muta-
tions were missed, and the pathogenic status of several
sequence variants remains unresolved. However, the
important practical implication of our study is that, given
the time and expense involved, it would be reasonable to
attach a low priority to BRCA1 mutation screening of
young isolated cases of breast cancer in the context of the
provision of a publicly funded and cost eVective diagnostic
service. A screen of this cohort of patients for BRCA2
mutations is in progress.
This study was supported by the NHS National Cancer Research and Develop-
ment Programme (UK) (project No NCP/B11/34).
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Figure 1 Pedigrees of cases in whom a pathogenic BRCA1 mutation was identified.
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Table 2 BRCA1 unclassified variants and polymorphisms
Exon Nucleotide change
Amino acid
change
Freq in
controls
Conserved in
mouse/dog
BIC
entries
11 2531 G/C Q804H 0.0 +/− 0
11 3537 A/G S1140G 0.0 −/+ 15
11 4158 A/G R1347G 0.01* −/+ 75
16 4931 A/G Q1604Q ND +/+† 16
16 5029 C/T P1637L 0.0 +/+ 11
18 5075 G/A M1652I 0.01 +/+ 8
intron 22 IVS22+8 T/C Unknown ND ND 2
3' untrans UGA+36 C/G Unknown ND ND 4
*As reported by Langston et al.7
†Nucleotide sequence is conserved in mouse and dog BRCA1 genes.
ND = not determined.
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Delineation of a new syndrome:
clustering of pyloric stenosis,
endometriosis, and breast cancer in
two families
EDITOR—Familial tendencies have previously been ob-
served for congenital pyloric stenosis, endometriosis, and
breast cancer. These conditions have never been consid-
ered to have shared aetiological origins and consequently
no previous attempts have been made to investigate an
association. For example, when obtaining family history
information for a child with pyloric stenosis, one would not
routinely request a description of adult onset conditions
such as endometriosis or breast cancer. Two families shar-
ing an unusual clustering of these three conditions (pyloric
stenosis, endometriosis, and breast cancer) were ascer-
tained at the familial cancer clinics of the Women’s College
and Princess Margaret Hospitals in Toronto.
Family 1 (fig 1) contains four confirmed cases of breast
cancer (below age 60), seven cases of endometriosis, five
cases of congenital pyloric stenosis, nine cases of polycystic
ovaries, and four cases of non-insulin dependent diabetes.
In a second unrelated family, a woman previously
diagnosed with premenopausal breast cancer, endometrio-
sis, and pyloric stenosis reported one other case of
congenital pyloric stenosis and four other cases of
endometriosis in her family (fig 1). It is the similar and
unusual presentation in these two families which suggests
that the clustering of pyloric stenosis, endometriosis, and
breast cancer may not be the result of chance.
A family history of breast cancer is known to be the most
significant risk factor for developing the disease. Approxi-
mately 5-10% of all cases are hereditary and accounted for
by mutations in cancer susceptibility genes BRCA1 and
BRCA2.1 2 Family 1 met our criteria for BRCA1 and
BRCA2 testing, with four known cases of breast cancer
diagnosed below the age of 60. Mutation analysis by direct
sequencing of the coding regions of BRCA1 and BRCA2 as
well as 1700 adjacent non-coding intronic base pairs was
performed by Myriad Genetic Laboratories (http://
www.myriad.com). No BRCA mutation was identified for
family 1. Family 2 was not tested for BRCA1 or BRCA2
mutations.
The aetiology of endometriosis remains uncertain,
although familial trends have been described.3 Four studies
found that there is an increased risk among first degree
relatives.4–7 A small twin study found 6/8 monozygotic and
0/2 dizygotic twin pairs had endometriosis.7 In family 2,
five women in three generations had endometriosis and in
family 1 seven women in three generations were given the
diagnosis. The pattern of inheritance is consistent with sex
limited, autosomal dominant inheritance.
A multifactorial genetic contribution for pyloric stenosis
has been well established, although its pathological basis
remains unknown. Twin studies have shown that there is a
25-40% concordance rate in monozygotic twins.8 9 Based
on pooled data from several family studies and assuming a
population prevalence of 0.3%, a relative risk for first
degree relatives compared to the general population was
1810; however, population based studies (unselected
patients) have not been done. Pyloric stenosis has recently
been linked to the locus of the neuronal nitric oxide
synthase (NOS1) gene, based on 27 families.11 The NOS1
locus was also examined for other multifactorial conditions
such as asthma (candidate gene)13 14 and multiple sclerosis
(no association).15 Family 1 has five documented cases of
surgically corrected pyloric stenosis in three males and two
females. Family 2 has a parent and child with PS, both
female.
In addition to endometriosis, family 1 contains nine
women with polycystic ovary syndrome (PCOS), including
one woman with non-insulin dependent diabetes mellitus
(NIDDM). PCOS and NIDDM have been shown to have
a shared aetiology.12 Women with PCOS have a unique dis-
order of insulin action and are at increased risk of develop-
ing NIDDM, which occurs substantially younger (in the
third to fourth decades) than it does in the general popula-
tion.
Breast cancer, endometriosis, and pyloric stenosis in
families 1 and 2 may be explained by separate genetic pre-
dispositions; however, the possibility that there is a
common genetic basis exists. It is the complex interplay
between environmental, hormonal, and genetic factors
which poses a challenge to understanding the aetiology of
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each condition. A future study of pyloric stenosis in a case-
control design may investigate any association with breast
cancer or endometriosis.
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Figure 1 Pedigrees of families 1 and 2. Proband is indicated by an arrow. The age of the subjects appears directly below symbol. CA = breast cancer
followed by age of diagnosis (dx); Psu = primary site of cancer was not known; Pr CA = prostate cancer; Cx CA = cervical cancer; TAH = total
abdominal hysterectomy; BSO = bilateral salpingo-oophorectomy; NIDDM = non-insulin dependent diabetes mellitus; CHD = congenital heart disease;
D&C = dilatation and curettage; SA = spontaneous abortion; SB = stillbirth.
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Punctate calcification of the epiphyses,
visceral malformations, and
craniofacial dysmorphism in a female
baby
EDITOR—We report a fetus with striking craniofacial
dysmorphism, brachydactyly, and cerebral and cardiac
malformations in addition to punctate calcification of the
epiphyses.
The mother was treated for tuberculosis seven years
before the pregnancy but there were no known systemic
illnesses or teratogenic influences during this pregnancy.
The mother’s first pregnancy resulted in a termination at
22 weeks of gestation for multiple congenital abnormali-
ties, but further details are not known.
The baby was the second child born to a 21 year old
mother. A termination was performed at 21 weeks of ges-
tation because of multiple anomalies seen on antenatal
scanning. Necropsy showed a female fetus (fig 1) with a
weight of 1544 g, consistent with 17 weeks’ gestation. The
crown-heel length was 16.4 cm and right foot length was
18 mm. Facial examination showed an open right eye with
exophthalmos, hypertelorism, a flat nasal bridge with
hypoplasia of the alae nasi, flattening of the midface, a
short philtrum with a well defined philtral groove, large
lips, and a wide mouth with micrognathia. The right ear
was simple and low set and the left ear was rudimentary
Figure 1 (A) Front view of fetus. (B) Hand of fetus. (C) Foot of fetus.
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and poorly formed. The palate was normal. Both hands
had brachydactyly involving all digits with short thumbs.
There were bilateral varus foot deformities and both feet
were rockerbottom in shape. The remainder of the
examination showed nuchal thickening, a short, broad
chest, and a straight spine. The genitalia were female with
a vaginal opening but there was clitoral hypertrophy and
prominence of the labial folds.
Internal examination of the brain showed enlargement of
both lateral cerebral ventricles, absent olfactory bulbs, and
an absent pituitary gland. The heart had a common trun-
cus arising from the right ventricle with a high ventricular
septal defect. The right adrenal gland was absent.
Histological sections showed that one umbilical artery was
rudimentary without a lumen. Examination of the placenta
showed no inflammatory changes. Unfortunately, no
histological studies were performed on bone.
Chromosome analysis showed an apparently normal
female karyotype but the quality of the preparation was
suYcient only to exclude numerical and large structural
abnormalities. Culture of the fetal cells failed and
peroxisomal studies and a 7-dehydrocholesterol level were
not performed.
Radiographs (fig 2) showed extensive calcification and
stippling in all epiphyseal areas. There was undermodelling
of the long bones with shortening of the humeri and rela-
tive widening of the diaphyses. There was poor calcification
and sagittal clefting of the vertebral bodies. Radiographs of
the hands and feet showed stippling in the carpal and tar-
sal bones and the fingers and toes were extremely short
with a single phalanx in the second to fifth digits and
almost absent ossification of the phalanges. The thorax was
short and broad with 11 pairs of ribs and there was poste-
rior dislocation of the hips. The couple chose not to attend
genetic counselling clinic.
This baby had an unusual pattern of malformations
including right exophthalmos, midface hypoplasia, rudi-
mentary ears, cerebral ventriculomegaly, a common
truncus arteriosus and ventricular septal defect, and
extreme brachydactyly in addition to calcific stippling of
the epiphyses. Epiphyseal stippling can be found in the pri-
mary chondrodysplasias,1 but the visceral abnormalities in
this baby are not typical of chondrodysplasia and the pres-
entation is neither consistent with brachytelephalangic
chondrodysplasia punctata (CP)2 3 or humerometacarpal
CP.4 5 One plausible diagnosis is Pacman dysplasia, a rare
condition in which stippling of the lower spine and epiphy-
ses has been found with bowing of the femora, spinal clef-
ting, and giant, multinucleated, osteoclast-like cells.6 7
Although a patent ductus was described in one child, Pac-
man dysplasia has not been reported with severe visceral
abnormalities or craniofacial dysmorphism as found in this
baby.
Stippling of the epiphyses is well known to be causally
heterogeneous,1 8 but syndromes with punctate calcifica-
tion and visceral malformations are rare. Two sibs were
described with short stature, ocular colobomata, midface
hypoplasia with a small nose, low set ears, and dysplastic
distal phalanges in addition to stippled epiphyses.9 A
second report of a girl with similar facial dysmorphism, a
right retinal coloboma and an incomplete atrioventricular
canal, coarctation of the aorta, enlargement of the anterior
horns of the lateral ventricles, and partial agenesis of the
corpus callosum concluded that these anomalies com-
prised a separate syndrome.10 Recently, a male baby with
punctate epiphyses and coronal clefting of the spine was
described with a Dandy-Walker malformation, hypogen-
esis of the corpus callosum and falx cerebri, a ventricular
septal defect, and bilateral cleft lip and palate.11 This child
also had craniofacial dysmorphism with telecanthus,
clouding of the corneas, a high nasal bridge and
retromicrognathia, and brachydactyly.
These cases show a degree of similarity to this baby with
calcific stippling in association with midface and nasal
hypoplasia, dysplastic ears, brachydactyly, and cranial and
cerebral malformations. However, the variable nature of
the accompanying anomalies makes it diYcult to be confi-
dent that these patients represent heterogeneity of the same
condition. Despite the incomplete clinical information in
our case, we believe that documentation of these
abnormalities will prove useful in view of the rarity of the
combination of features and the paucity of reports describ-
ing epiphyseal stippling and malformations.
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Figure 2 Radiograph of fetus showing punctate
calcification of epiphyseal areas and stippling of carpal and
tarsal bones.
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Unexpected high frequency of de novo
unbalanced translocations in patients
with Wolf-Hirschhorn syndrome
(WHS)
EDITOR—Wolf-Hirschhorn syndrome (WHS), first de-
scribed independently in 1965 by Wolf et al1 and
Hirschhorn et al,2 is a well defined multiple congenital
anomalies/mental retardation syndrome resulting from
deletion involving chromosomal band 4p16.3 with a mini-
mal critical region of 165 kb.3
DiVerent mechanisms are responsible for WHS, includ-
ing terminal 4p deletions, familial translocations, and de
novo complex chromosomal rearrangements such as
unbalanced translocations. The frequency of transloca-
tions in WHS as a result of parental chromosomal translo-
cations is estimated to be 5 to 13%,4 5 whereas the rate of
sporadic translocations in WHS was suggested to be 1.6%
(2/120).5 A few isolated cases with de novo
translocations5–12 resulting in WHS have been described
recently. The trisomic segment, however, often could not
be defined owing to the lack of specific cytogenetic
techniques.5 6 8 13–15
Here we report six patients with unbalanced transloca-
tions, t(4p;8p) and t(4p;7p), respectively, and discuss their
phenotypic abnormalities.
Since 1996 we have performed clinical, molecular,
cytogenetic, and molecular-cytogenetic investigations in a
total of 22 patients with clinical signs of Wolf-Hirschhorn
syndrome. These patients were all seen by one of the
authors. In five of them (22%), the combination of
cytogenetic and molecular investigations showed a de novo
unbalanced translocation; in a sixth patient the de novo
occurrence of the translocation could not be confirmed
because no blood sample from the father was available.
The clinical findings of patients 1-5, who all presented
with characteristic features of WHS, are summarised in
table 1. Patient 6 (CL220585/87E1624) had some
additional findings listed in table 1.
The combination of Hirschsprung disease and hydro-
cephalus was suggestive of CRASH syndrome in patient 6,
but SSCP analysis of the L1CAM gene was normal.
Chromosome studies including GTG banding were per-
formed on peripheral blood lymphocytes according to
slightly modified standard techniques.16
DNA from cosmids pC847.351,17 L21f12 (D4S180), and
L228a7 (D4S81)18 and inter-Alu PCR products19 from YAC
877G6, 405D10, 794D12, 225D2, and 435A11 (CEPH)
were labelled with digoxigenin using a BRL nick translation
kit (Gibco, Life Technologies Inc, Gaithersburg, MD, USA).
Labelled cosmid and YAC DNA was separated from
unincorporated nucleotides by using 1800 ml Centricon 30
(Amicon Inc, Beverly, MA 01915, USA) filters. FISH was
performed as described by Lichter et al.20 Labelled cosmid
DNA (50 ng) or YAC DNA (100 ng) was mixed with human
Cot-1 fraction DNA to suppress repetitive sequences or
block non-specific hybridisation. Hybridisation was detected
using monoclonal anti-digoxin, anti-mouse IgG FITC con-
jugate and anti-rabbit IgG FITC conjugate (Sigma Immuno
Table 1 Clinical findings in patients 1-5 with t(4;8) and patient 6 with t(4;7)
Patient 1
(CG/96E0600)
Patient 2
(DT/92E1657)
Patient 3
(LF/96E0551)
Patient 4
(NR/97E877)
Patient 5
(AS/94E1416)
Patient 6
(CL/87E1624)
Anthropometric data
Birth (gestational weeks) 39 36 38 40 40 41
Weight (g) 2900 (−1.0 SD) 2120 (−1.2 SD) 1800 (−3.4 SD) 2240 (−3.6 SD) 2200 (−3.7 SD) 2950 (−1.6 SD)
Length (cm) NR 46 (−0.4 SD) 42 (−2.9 SD) 47 (−3.2 SD) 45 (−4.3 SD) 48 (−2.5 SD)
OFC (cm) 31.5 (−2.4 SD) 30.5 (−1.9 SD) NR 31.5 (−2.7 SD) 32 (−2.3 SD) 34 (−1.6 SD)
Age at examination (y) 11⁄12 35⁄12 36⁄12 2 510⁄12 12
Weight (g) 5240 (−3.8 SD) 9060 (−3.2 SD) NR NR NR 29 000 (−2 SD)
Height (cm) 64.2 (−4.4 SD) 89 (−2.7 SD) 84.5 (−6.7 SD) 72 (−5 SD) 91 (−4.4 SD) 133 (−2.4 SD)
OFC (cm) 41.3 (−3.5 SD) 46.5 (−2.2 SD) 44 (−5.0 SD) 42 (−4.6 SD) 46 (−3.5 SD) 54 (mean)
Dysmorphic features
Hypertelorism + + + + + +
Strabismus + − + + + +
Broad, large mouth − + − − + +
Downturned corners of mouth + + + + + +
Micrognathia + + + + +
Cleft lip/palate − − + + + −
Dysplastic ears + + + + + +
Preauricular tag − − + − − −
Internal findings
Heart defect − − ASD ASD − −
Genital anomalies − + NR − − +
Neurological development
Sitting age (mth) 13 20 60 − 24 36
Walking age (y) 2 35⁄12 69⁄12 − 5 ?
Simple words (y) 26⁄12 − − − − ?
Understanding of speech ++ ++ (+) − − ++
Seizures − + + + + +
Additional findings Oligohydramnios
Bilateral pneumothorax
Flexion contractures of large joints
Hypoplasia of corpus callosum
Hirschsprung disease
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Chemicals, St Louis, USA) and counterstained using
propidium iodide or DAPI.
A cosmid derived from D4S96, the 8p telomere probe
and 7p distal probe (Oncor, Gaithersburg, VA, USA) and
the whole chromosome paints 4 and 8 (AGS, Heidelberg,
Germany/Oncor, Gaithersburg, VA, USA) were hybridised
according to the manufacturer’s instructions. For the
hybridisations, clone pGXba11/34021 was used as centro-
meric control for human chromosome 4.
Genomic DNA was prepared from peripheral blood
lymphocytes or EBV transformed lymphoblastoid cell lines
from patients and their parents according to previously
described techniques.22 23
Genotyping of chromosome 4p was performed using the
following previously described microsatellite markers:
D4S1182 (Acc ID GDB 19723924), D4S43 (Acc ID GDB
12436024), ADRA2C (Acc ID GDB 37083425), HOX7
(Acc ID GDB 15699126 27), D4S403 (Acc ID GDB
18810628), D4S2366 (Acc ID GDB 684453), D4S2639
(Acc ID GDB 685881), and D4S2397 (Acc ID GDB
683982). A new microsatellite, 75B9Rep, was generated by
one of the authors based on sequence information of cos-
mid 75B9A (Acc No Z69651) which is derived from the
distal end of the Huntington’s disease cosmid contig.29 Oli-
gomers were designed from sequences flanking the
compound dinucleotide repeat (CT)2G(CT)26(CA)14. The
following primer sequences were used for the amplification
of the repeat, forward primer 5' CTGAACTTTATC-
CAATTAGTCTTG 3' and reverse primer 5' GAATCTT-
TCTGTCCCACGAT 3'. This primer set amplifies a 227
bp DNA fragment product. PCR reactions were performed
in 10 µl volumes containing 100 ng DNA, 0.5 U GenecraftR
Taq polymerase, 1 × GenecraftR PCR buVer, 2 µmol/l
dNTP, 4 pmol/l of each primer, 1 µCi 32P-dCTP (3000
Ci/mmol/lol, Amersham), and 2 mmol/l MgCl2. Forma-
mide (2%) was added to increase stringency of the
reaction. After an initial denaturation of one minute, 30
cycles of one minute at 94°C, 30 seconds at 57°C, and 30
seconds at 72°C were carried out in a Crocodile IIIR (App-
ligene) thermocycler. The PCR products were resolved on
6% polyacrylamide gels flanked by a sequence ladder
(M13, −40) as size marker. The Hu4/Hu5 (Acc ID GDB
249651) primer pair amplifies the CAG repeat of the
huntingtin gene. Primer Hu4 has been published by Riess
et al25 (primer sequence: Hu4 5' ATGGCGACCCT-
GGAAAAGCTGATGAA 3'), and primer Hu5 has been
published by Rubinsztein et al30 (primer sequence: Hu5 5'
GGCGGTGGCGGCTGTTGCTGCTGCTGC 3').
Figure 1 (A) Chromosomes 4 of patient 2 showing an additional G positive band in 4pter. (B) Chromosomes 4 of patient 4 showing same length of 4p
but diVerent G banded pattern.
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At the beginning of our study of 22 WHS patients, we
reanalysed the chromosomes in lymphocytes by standard
Giemsa banding techniques. At a banding resolution of at
least 450 bands per haploid genome,31 an additional small
G positive band was observed on the distal short arm of
one chromosome 4 in patients 1 and 2 (fig 1A) and an
unbalanced translocation was suspected in patients 3, 4,
and 5 (fig 1B). In patient 6, a deletion of 4p with
breakpoints in 4p16.2 was suggested. Thus, we suspected
an unbalanced translocation between the short arm of one
of the chromosomes 4 and another unidentified chromo-
some in patients 1-5, while the cytogenetic aberration in
patient 6 appeared to be a simple deletion.
Chromosomal analysis in all participating parents
showed a normal karyotype. In patient 5 the father was not
available. The remaining 16 patients of this study are
described elsewhere (D Wieczorek, manuscript in prepara-
tion).
DiVerent cosmids were used to confirm the clinical
diagnosis of WHS in all patients. In patients 1, 2, and 5, a
deletion of D4S96 (Oncor) and of cosmids pC847.351 and
L228a7 on one homologue of chromosome 4 was noted
(fig 2A). In patients 3 and 4, YAC 405D10 was also deleted
on one homologue. In patient 5, the size of the deletion was
determined by FISH only. Cosmids pC847.351, L21f12,
and L228a7 and YACs 877G6 and 405D10 were deleted
on one chromosome 4, whereas YACs 794D12, 225D2,
and 435A11 were present on both chromosomes 4 (table
2).
Table 2 Extent and origin of the 4p deletion in patients 1–6
Distance from
4pter
Microsatellite
marker Cosmid YAC Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
∼ 200 kb pC847.351 (D4F26) del del del del del del
∼ 1.2 Mb pC678 (D4S96) del del del del del del
∼ 1.9 Mb L75B9 Rep M M M
∼ 2.0 Mb D4S1182 NI M NI
∼ 2.2 Mb D4S43 33c6 (D4S43) M NI NI M
∼ 3.0 Mb Hu4/Hu5 M M NI NI
∼ 3.3 Mb L21f12 (D4S180) del del del
∼ 3.8 Mb ADRA2C NI M M
∼ 3.8 Mb L228a7 (D4S81) del del del del del del
∼ 5.5 Mb Hox7 ND ND NI NI
∼ 7.0 Mb 877G6 del ND
∼ 8.8 Mb D4S2366 ND ND M
∼ 13.0 Mb 405D10 del del del ND
∼ 14.0 Mb 794D12 ND ND ND ND
∼ 16.5 Mb D4S403 ND ND ND
∼ 19.8 Mb 225D2 ND ND ND ND
∼ 21.5 Mb 435A11 ND ND
∼ 23.0 Mb D4S2639 ND ND ND ND
∼ 34.0 Mb D4S2397 ND ND ND ND
del: deleted; ND: not deleted; NI: not informative; M: maternally deleted.
Figure 2 FISH results in patient 4. (A) FISH with cosmid pC847.351 showing lack of signal in one chromosome 4p. (B) FISH with wcp(4) showing
fluorescent signals on the entire length of both chromosomes 4 except for the terminal region of one chromosome 4. (C) FISH with distal 8p probe showing
two signals in the distal region of 8p and an additional signal in the distal short arm of one chromosome 4.
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FISH staining with a whole chromosome 4 paint (AGS/
Oncor) in all six patients gave hybridisation signals along
the entire length of both chromosomes 4 except for the
distal part of the aberrant chromosome 4p (fig 2B). Both
chromosomes 8 showed hybridisation signals along the
entire length with whole chromosome paint 8 (AGS), but
also on one chromosome 4 in patients 1-5. FISH with an
8p telomere probe (Oncor, Gaithersburg, VA, USA)
showed signals on both chromosomes 8 and an additional
signal on one chromosome 4 (fig 2C).
Based on these findings we determined the karyotype of
patients 1 and 2 as 46,XX,der(4),t(4;8)(p16.3;p23.1).ish
t(4;8)(wcp4−, wcp8+, 8ptel+, pC847.351−, D4S96−,
228a7−; wcp4−, wcp8+, 8ptel+) and in patients 3, 4, and
5 as 46,XX,der(4),t(4;8)(p16.2;p21).ish t(4;8)(wcp4−,
wcp8+, 8ptel+, pC847.351−, D4S96−, 228a7−,
405D10−; wcp4−, wcp8+, 8ptel+).
FISH was also performed in the parents of patients 1-4
and the mother of patient 5. Normal results were detected
with D4S96 (Oncor) and with the 8p telomere probe
(Oncor). We conclude that the translocation t(4;8)
occurred de novo in all patients. However, in patient 4 one
could not exclude that the translocation may be inherited
from the father.
To identify the chromosome involved in the transloca-
tion of patient 6, we used diVerent paints and telomeric
probes of G negative bands. Additional signals on chromo-
some 4 were noted with distal 7p probe (Oncor) (fig 3). We
determined the karyotype in patient 6 as
46,XY,der(4),t(4;7)(p16;p22).ish t(4;8)(wcp4−, 7ptel+,
pC847.351−, D4S96−, 228a7−; wcp4−, 7ptel+). Balanced
translocations in his parents were excluded with FISH
using D4S96 and 7ptel in combination with pGXba11/
340.
The results of the analyses of polymorphic markers are
listed in table 2. Blood samples from the father of patient 5
were not available. Therefore, the size of the deletion was
determined by FISH only. DNA from patient 4 was not
available to identify the origin of the deletion.
In patients 1, 2, 3, and 6, the maternal allele was absent
and in patients 4 and 5 the origin of the deletion remains
undetermined. In patients 1, 2, and 6, the deletion 4p was
at least 3.8 Mb in size and in patients 3-5 the size of the
deletion can be estimated to be 13 Mb.
In our study of 22 patients with Wolf-Hirschhorn
syndrome, a de novo translocation was present in 5/22
(22.7%) and a familial translocation in 3/22 patients
(13.6%) (manuscript in preparation). In one additional
patient (patient 5) a de novo translocation was suspected,
but could not be confirmed. To our knowledge, such a high
rate of proven de novo translocations in WHS has not pre-
viously been reported. This could be explained by the
refined molecular-cytogenetic techniques such as FISH
analysis and microsatellite analysis used here. In particular,
de novo unbalanced translocations between the short arms
of chromosomes 4 and 8 seem to be not uncommon in
WHS. Müller-Navia et al10 described one fetus and Petit et
al11 12 another male patient with this chromosomal aberra-
tion.
The breakpoints of 4p and 8p diVer in our patients,
which makes sequence homologies between these chromo-
somal segments less likely. Thus, it is of great interest that
Kogi et al32 and Gondo et al33 described a new class of tan-
demly repeated satellite DNA elements on chromosome 4p
and 8p. They identified a tandem array of several RS447
sequence copies in 4p15 and distal 8p. This repeat was
suggested to be responsible for formation of inversion
duplication 8p34 and might probably explain the higher fre-
quency of translocations between 4p and 8p.
Moreover, other chromosomes also, for example chro-
mosome 7 in patient 6, occur in de novo unbalanced trans-
locations involving the short arm of chromosome 4. Our
findings support the hypothesis of Reid et al35 that cryptic
complex chromosomal rearrangements are more common
than usually disclosed by light microscopy of convention-
ally stained chromosomes. Selection bias was unlikely, as
we investigated blood specimens of all children with known
WHS and with a tentative diagnosis of WHS.
Determination of the origin of the deletion showed that
in all four patients in whom this was possible the maternal
allele was absent, which is in contrast to published data. To
avoid bias owing to familial translocations, which are
mostly inherited maternally in a 2:1 ratio,36 the patients’
parents were also investigated by conventional karyotyping
and FISH analysis. We reviewed cases in which the origin
of the 4p deletion was determined and found 27 paternally
inherited and six maternally inherited deletions.7 15 37–45
Thus, 82% of reported patients with WHS show a
paternally derived deletion.
As to the published patients with maternally inherited
deletions, the patient Val described by Anvret et al39 had a
more complex chromosomal rearrangement causing WHS.
Further cytogenetic investigations were not possible.
Patients 3 and 6 from the report of Dallapiccola et al44 and
case 2 of Thies et al42 presented with a de novo, maternally
inherited deletion with breakpoints in 4p16.1, 4p16.3, or
4p13, respectively. However, FISH analysis with whole
chromosome 4 paint was not performed to exclude a cryp-
tic translocation. In the patient described by Greenberg et
al,38 cryptic translocation in the mother was discussed, but
not investigated. Patient 3 in the report of Kant et al37 with
maternal origin of the deletion had an unbalanced
karyotype based on a cryptic translocation t(4;8) in the
mother. Thies et al42 described a third patient with de novo
deletion and also a maternally inherited deletion. On the
other hand, in two WHS patients with unidentified de novo
translocations40 the deletion was of paternal origin.
DiVerent explanations for the preponderance of pater-
nally inherited deletions are possible, for example, statisti-
cal deviation or real biological phenomena such as
increased mutation rates in sperm or genomic imprinting.41
An excess of rearrangements in male meiosis, related to
diVerences between the mechanisms of sperm and egg
production, have also been discussed.44
One aim of our study was to determine whether the
WHS phenotype is influenced by the trisomic autosomal
segment. The clinical findings in our patients 1-5, in previ-
ously published patients with familial translocations
Figure 3 FISH results in patient 6. FISH with distal 7p probe showing
two signals in the distal region of 7p and an additional signal in the distal
short arm of one chromosome 4.
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t(4;8),37 46–52 in patients with partial trisomy 8 owing to
inversion duplication53–59 or direct duplication,60 61 respec-
tively, and in patients with WHS6 62 are compared in table
3. There are several clinical signs which are usually present
in patients with partial monosomy 4p as well as in those
with partial trisomy 8p, such as mental retardation,
muscular hypotonia, prominent forehead, broad nasal
bridge, large mouth, dysplastic ears, and congenital heart
defects. Thus, these features are by no means specific
enough to distinguish between the phenotypes.
The face in WHS is much more characteristic than in
partial trisomy 8p and is not significantly influenced by the
presence of this trisomic segment. All in all, it seems to us
impossible to diVerentiate clinically between patients with
WHS resulting from monosomy 4p and WHS resulting
from unbalanced translocation 4p;8p. This agrees with the
conclusions of other authors.37 47–51
As to patient 6, to our knowledge, no other patient with
a de novo translocation t(4p;7p) has been described
before.63 64 However, many patients with trisomy 7p result-
ing from familial translocations have been reported. These
patients are not listed in table 3 because a considerable
influence on the phenotype by monosomic autosomal seg-
ments cannot be excluded. Only those patients with distal
duplication 7p are included.65–67 The characteristic, clini-
cally recognisable phenotype in trisomy 7p encompasses
delayed closure of fontanelles, sparse or even lack of
eyebrows, a short nose with a low and broad nasal bridge,
small upper and prominent, full lower lip, micrognathia,
hypotonia, congenital heart defect, and delayed speech
development.65 Macrocephaly and enlarged cerebral ven-
tricles were only described in one patient.66 One might
speculate that relative macrocephaly in patient 6, which is
highly unusual in patients with WHS, may be the result of
the duplicated segment in 7p. Delicado et al66 noted intes-
tinal malrotation with dilatation of the sigmoid and left
colon in their patient, but excluded Hirschsprung’s disease.
Our patient presented with similar anomalies of the intes-
tines. We assume that this clinical sign, which has not been
described in WHS before, may be caused by the
duplication 7p. In conclusion, the overall phenotype in
Table 3 Clinical signs of patients with duplication 8p, with unbalanced translocation t(4p;8p), with monosomy 4p, with trisomy 7p, and reported patients
inv dup 8p* dir dup 8p† t (4p;8p)‡
Our
patients 1–5 WHS§
Our
patient 6 Trisomy 7p¶
Duplicated segment At least 8p21.1-p21.3 8p22-p23.1 or 8p21.3-p22 8p21-pter 8p 7/24 7p 7p11.2-pter
−
8p23.1-pter
Monosomic segment 8p23.1-pter in 6 cases none 4p15.3-pter 4p 4p14-16 4p 7q36-qter
−
4p16.3-pter
De novo 14/15 − 0/8 4/5 8/11 + 2/3
Sex 12 F; 8 M 3 F; 3 M 2 F; 6 M 5 F 14 F; 10 M M 2 M; 1 F
Mental retardation 20/20 5/6 8/8 5/5 22/23 + 3/3
Muscular hypotonia 13/13 0/6 4/4 4/5 20/24 + 2/2
Seizures/EEG anomaly 1/2 0/6 5/8 4/5 18/24 + NR
Normal birth weight 7/8 4/4 0/6 0/5 0/13 − 2/3
Low birth weight (<3rd centile) 1/17 0/4 6/6 5/5 13/13 + 1/3
Postnatal normal stature 3/6 3/5 0/6 0/5 4/23 − 0/2
Postnatal short stature 2/6 2/5 6/6 5/5 19/23 + 2/2
Absence of dysmorphic signs 10/10 2/3 0/8 0/5 0/23 − 0/3
Craniofacial anomalies
Microcephaly 3/14 0/6 5/5 5/5 20/24 − 2/3
Macrocephaly 2/14 0/6 0/5 0/5 0/13 − 1/3
Wide open fontanelles 0/1 NR NR 3/5 NR + 3/3
Flat occiput 8/13 0/3 1/1 1/2 NR − NR
Prominent forehead 13/18 3/6 5/5 5/5 8/11 + 2/3
Prominent glabella 0/5 0/3 4/5 3/5 18/24 − 0/3
Hypertelorism 3/15 1/3 7/7 5/5 20/24 + 3/3
Hypotelorism 3/15 0/3 0/7 0/5 0/13 − 0/3
Strabismus 1/1 0/3 3/4 4/5 13/23 + NR
Broad nasal bridge 11/17 3/6 6/6 5/5 20/24 + 1/3
Narrow nasal bridge 2/6 0/3 0/6 0/5 0/13 − 1/3
Anteverted nares 7/18 0/3 1/4 0/5 NR − 2/3
Beaked nose 3/6 0/3 2/6 0/5 6/11 + 1/2
Short philtrum 1/6 1/6 7/7 3/5 13/13 + 1/2
Long philtrum 2/6 0/6 0/7 0/5 0/13 − 2/3
Large mouth 14/19 0/6 4/5 2/5 10/13 + 1/3
Downturned corners of mouth 1/5 0/3 3/4 5/5 13/13 1/3
Thin upper lip 9/17 2/6 2/5 4/5 6/13 + 3/3
High arched palate 10/13 0/3 1/3 0/2 2/11 + NR
Cleft lip/palate NR 0/3 4/5 3/5 8/24 − NR
Abnormal dentition 12/13 1/5 3/3 1/1 1/11 − 1/1
Micrognathia 6/8 0/6 6/8 5/5 18/24 + 3/3
Large chin 2/8 1/6 1/5 0/5 0/13 − 1/3
Small ears 0/9 0/3 0/3 0/5 1/11 + NR
Large ears 8/9 0/3 0/3 0/5 2/11 − NR
Dysplastic ears 15/18 0/3 6/7 5/5 18/24 + 3/3
Brain anomalies
Enlarged ventricles 2/6 0/3 1/2 0/2 NR + 1/1
Agenesis of corpus callosum 4/6 0/3 0/2 0/2 NR + NR
Cortical atrophy 2/6 0/3 0/2 0/2 NR + NR
Congenital heart defect 5/12 0/6 3/5 2/5 6/24 2/3
Scoliosis 6/13 0/3 1/3 0/5 3/13 − NR
Hypoplastic external genitalia 1/2 0/5 2/2 1/4 3/11 + 2/2
Hypospadias NR 0/5 5/5 / 7/10 + 0/2
Renal anomalies 1/2 0/3 2/5 1/3 2/11 + NR
Inguinal/umbilical hernia 3/13 0/3 2/2 0/3 NR − NR
Megacolon NR 0/3 0/2 0/3 NR + 1/1
*Refs 53–58, 61.
†Refs 60 and 61.
‡Refs 37, 46–51; 10 was not included because of lack of clinical description.
§Refs 6 and 62.
¶Refs 65–67.
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patient 6, in contrast to patients 1-5, appears to be consid-
erably influenced by the trisomic region of 7p (table 3).
In summary, we show that de novo translocations caus-
ing WHS are more frequent than previously estimated. We
recommend performing FISH analysis with wcp(4) in
every WHS patient to exclude or confirm a de novo trans-
location as a common mechanism causing WHS. Also
patients with cytogenetically visible deletions should be
investigated by molecular-cytogenetic techniques to ex-
clude cryptic rearrangements. Moreover, de novo translo-
cations t(4p;8p) in WHS patients are more frequent than
previously suspected.
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Mosaicism for a dup(12)(q22q13) in a
patient with hypomelanosis of Ito and
asymmetry
EDITOR—Hypomelanosis of Ito (HI) (MIM 146150) is an
aetiologically heterogeneous physical finding characterised
by a swirling pattern of hypopigmentation of the skin, typi-
cally distributed along the lines of Blaschko, reflecting pig-
mentary mosaicism. Chromosomal abnormalities are
common and very heterogeneous. They include X;auto-
somal translocations and mosaicism of aneuploidy, seg-
mental trisomies, or monosomies.1–5 As HI is not a specific
disorder, it has also been referred to as pigmentary
mosaicism.6 This report adds a further chromosomal
anomaly which has not been described in pigmentary
mosaicism previously.
The proband was the first son born to a 29 year old
mother and a 30 year old father. There was no family his-
tory of recurrent abortions, consanguinity, or mental retar-
dation. He was born by caesarian section at term after an
uncomplicated pregnancy with a weight of 3560 g (50th
centile), a length of 50 cm (50th centile), and an occipito-
frontal circumference (OFC) of 32 cm (<3rd centile).
Apgar scores were 8, 9, and 10. No complications were
reported in the perinatal period. Despite delayed psycho-
motor milestones (sitting at 9 months, walking at 2 years,
first words at 3 years), the first evaluation was only done at
the age of 5 years. At the age of 10 years he was referred to
our endocrinological outpatient clinic because of crypt-
orchidism and glandular hypospadias. At this time he was
found to be a shy and uncommunicative boy. He showed
moderate mental retardation and attended a school for
handicapped children. He had a height of 1.3 m (3rd cen-
tile), a weight of 26 kg (3rd centile), and an OFC of 50 cm
(<3rd centile). On physical examination, mild facial asym-
Figure 1 Patient at the age of 10 years.
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metry, epicanthic folds, a broad nose with a broad nasal tip,
retrognathia, dysplastic ears, and a low set posterior hair
line were noted (fig 1). Areas of linear hypopigmentation
were distributed along the lines of Blaschko and were more
evident on the legs. He also showed hemihypertrophy of
the right leg, bilateral pes equinovarus, and pectus excava-
tum. There were no organic defects.
Chromosome analysis of peripheral lymphocytes showed
the karyotype 46,XY[91]/46,XY,add(12q)[9]. The GTG
banding pattern was suggestive of an interstitial duplica-
tion involving chromosomal segment q13-q21 or q13-q22
(fig 2). Parental karyotypes were normal. Fibroblast
cultures were obtained from a normal and a hypopig-
mented skin area on the left arm. Fifty cells from each first
subculture were analysed and identified 70% abnormal
cells in the normal skin and 15% abnormal cells in the
hypopigmented skin fibroblast culture. In addition, 2/50
cells from the normally pigmented skin showed the karyo-
type 46,XY,del(7)(q31).
Multiplex-FISH (M-FISH) allows the identification of
chromosomes with distinct colours and was performed as
described elsewhere.7 The M-FISH analysis showed that
the der(12) consisted of chromosome 12 material only,
excluding an interchromosomal rearrangement. No other
abnormalities were noted. In order to characterise the
der(12) in more detail a chromosome 12 specific multicol-
our bar code was constructed with YAC clones from the
CEPH library, as previously described8 (table 1). On the
der(12), two signals (blue) were observed for the 12q13
specific YAC 926h3 (fig 2). These signals were located
close to each other indicating a duplication of the
respective region. The 12q21-22 specific YAC 923a3
displayed a normal signal (red) distal and a weak signal
proximal to the 926h3 double spot, indicating that this
particular YAC is partially duplicated and spans a
breakpoint of the duplication. The multicolour banding
pattern clearly showed an inverted duplication involving
the segment 12q13-q21/22 and allowed the diVerentiation
between the two possibilities of inverted duplications
(pter-q13::q22-q13::q22-qter versus pter-q21/22::q22-
q13::q22-qter). Using the GTG banding pattern in
addition to the FISH results, the structure of the der(12)
could be designated as dup(12)(pter-q13::q22-q13::q22-
qter) (fig 2). The patient was thus mosaic for a pure
trisomy of the segment 12q13-q21.
Figure 2 FISH and GTG banding. (A) M-FISH painted the elongated long arm of chromosome 12 homogeneously, indicating a duplication of
chromosome 12 material. (B) Application of a multicolour chromosome 12 specific bar code allowed the identification and mapping of the duplicated
segment. On the derivative chromosome 12, two signals corresponding to YAC 926h3 (blue) are located close to each other. The 12q21-22 specific YAC
923a3 displayed a weak red signal proximal to the 926h3 double spot in addition to a normal red signal distal to the blue double spot. Thus, the
rearrangement represents an inverted duplication of the segment 12q13-q21/22 with upward direction, dup(12)(pter-q13::q22-q13::q22-qter).
(C) Breakpoint analysis using GTG banding of chromosome 12, which is in concordance with the results of FISH analysis.
Table 1 Barcode set 12-2
YAC Band Fluor Pseudocolour
924h12 p12 Cy3.5, FITC Lilac
952a6 p11.2-p12 Cy3 Green (dark)
754a1 12q12 Cy5.5 Yellow
926h3 12q13 Cy3.5, Cy3 Blue
923a3 12q21/q22 FITC Red
908g3 12q24.1-q24.2 Cy5 Green (light)
751b8 12q24.3 Cy3, FITC Green
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In many kinds of de novo chromosomal aberrations, it is
impossible to determine the chromosomal origin of the
extra material by banding patterns alone and characterisa-
tion of the rearrangement often needs FISH analysis with
single copy probes. In the present case, a partial trisomy
12q was suspected from the G banding pattern and was
confirmed by M-FISH within a single hybridisation
experiment. Chromosome specific bar codes obtained
from well characterised YAC clones have been shown to be
useful for characterising chromosomal rearrangements.8
By performing multicolour FISH using a set of chromo-
some 12 specific YAC clones, the type of duplication in the
proband was identified as inverted. Moreover, we could
also diVerentiate between the two possibilities of inverted
duplication occurring upwards or downwards on the chro-
mosome arm. Using YAC mapping data and GTG
banding pattern analysis, the rearrangement in the
proband was defined as an inverted duplication in an
upward direction involving the segment 12q13-q22. This
case illustrates the potential of multicolour chromosome
specific bar codes for the characterisation of intrachromo-
somal rearrangements by a single hybridisation experi-
ment. Other methods, such as CGH and reverse painting,
in general allow the accurate mapping of over-represented
regions. However, CGH analysis would have failed in this
case because of the mosaicism with a high percentage of
normal cells. At best, reverse FISH could only allow the
diVerentiation between direct and the two types of inverted
duplication. In contrast, the fortuitous determination of a
breakpoint YAC from the bar code enables mapping of the
duplication at a molecular level, which would be impossible
by CGH or reverse painting.
The trisomy 12q13-q22 was detected in 10% of periph-
eral lymphocytes, in 70% of fibroblasts obtained from the
normally pigmented skin, and in 15% of fibroblasts from
the hypopigmented skin. Thus, the proportion of abnormal
cells in the two diVerent skin areas did not correlate with
the skin pigmentation in the patient. This is not surprising
as fibroblasts were investigated and it is expected that
melanocytes, as the carriers of the biochemical defect, have
a diVerent distribution, because the two cell types have dif-
ferent embryological derivations. As a consequence, the
selection of the skin biopsy area should not be guided by
the localisation of skin pigmentation abnormality, and
biopsy of more than one site may be required to identify the
chromosomal anomaly in fibroblasts. A deletion 7q was
found in two fibroblast cells of the normally pigmented
skin, but not in other cells. We do not know if deletion 7q
is the result of a cultural artefact or a third cell line in skin
fibroblasts. The low proportion of abnormal lymphocytes
shows the importance of analysis of a large number of cells.
Moreover, a normal karyotype in lymphocytes of HI
patients does not rule out a chromosomal defect, as has
been shown for many HI associated chromosomal anoma-
lies, which were detected only in fibroblasts but not in
blood cultures.5 Like the proband described here, more
than 70% of HI patients have one or more abnormalities of
the central nervous system, the musculoskeletal system,
facies, epidermal structures, and inner organs. The
variability of the features associated with HI can be
interpreted as a consequence of diVerent chromosomal
imbalances. Our proband also showed asymmetrical clini-
cal features, which can also be considered as a non-specific
sign of chromosomal mosaicism and as an indication for
repeated chromosomal analysis of diVerent tissues, espe-
cially if it is associated with mental retardation or dysmor-
phic features or both.9
The proband’s phenotype is diVerent from other patients
with trisomy of a more distal part of 12q. Trisomy for the
segment 12q13-q22 has not been described previously and
a characteristic phenotypic pattern cannot be determined.
To our knowledge, only three other patients have been
reported with an interstitial duplication 12q.10 11 All of
them showed mosaicism suggesting that non-mosaic inter-
stitial trisomy 12q may be lethal.
Cytogenetic diagnosis of structural mosaicism enables
accurate genetic counselling of families. Given that the
parents have normal karyotypes, as in the present family,
the recurrence risk is very small. Mosaicism of structural
abnormalities with a 46 chromosome complement is rare,
and a significant proportion of such cases are direct or
inverted duplications.12 If chimerism were excluded, a
postzygotic origin of the rearrangement in a chromosoma-
lly normal conceptus can be postulated for intrachromo-
somal duplications, which would rule out the small risk of
parental gonadal mosaicism.
In summary, the present case stresses the importance of
careful chromosomal analysis of diVerent tissues in
patients with pigmentary anomalies or asymmetrical clini-
cal findings or both, and has shown the usefulness of mul-
ticolour FISH with single copy probes resulting in
chromosome specific bar codes to characterise intrachro-
mosomal rearrangements.
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An analphoid supernumerary marker
chromosome derived from
chromosome 3 ascertained in a fetus
with multiple malformations
EDITOR—We report a case in which a termination of preg-
nancy for fetal abnormality at 18 weeks’ gestation showed
a supernumerary marker chromosome. This extra chromo-
some did not hybridise to any alphoid probes and was
found to have a chromosome 3 origin when investigated by
M-FISH.
An anomaly ultrasound scan was performed because of
raised alphafetoprotein and beta HCG levels at 17 weeks’
gestation in a 32 year old, primigravida mother. The scan
showed a large and cystic left kidney, banana sign, and
absent cisterna magna, and signs of an open sacral spina
bifida. The pregnancy was terminated and necropsy
showed a male fetus consistent with 18 weeks’ gestation
with no dysmorphic facial features. A high arched palate
with a small amount of postnuchal oedema was noted as
well as a single transverse palmar crease on the right hand.
Inspection of the back showed a 1.3 cm long lumbosacral
myelomeningocele with protruding lower lumbar spinal
cord. On internal examination the cerebral hemispheres
were fully cleaved and appeared fluctuant suggesting the
possibility of internal hydrocephalus. The posterior fossa of
the brain was reduced in anteroposterior diameter as well
as appearing deep and funnel shaped, and the extension of
the cerebellar tonsils was below the level of the foramen
magnum. These findings are consistent with Arnold-Chiari
malformation. There was marked asymmetry of the
kidneys; the right kidney showed normal fetal lobation and
shape but the left kidney was very large and had thin,
translucent, subcapsular cysts, especially at the lower pole.
The cut surface showed a poor demarcation between the
cortex and medulla and the presence of cysts in most of the
renal parenchyma. These findings are consistent with
cystic renal dysplasia. The placenta was unremarkable and
the cord had three normal blood vessels.
The chromosomes of the abortus were examined from
fetal skin fibroblasts derived using the method of Fisher et
al.1 The metaphases from the fetal fibroblasts and parental
blood were GTL banded using a modification of the
method of Seabright.2 The abortus showed a male
karyotype with a metacentric supernumerary marker chro-
mosome approximately the size of a G group chromosome
in 17 out of 30 (57%) metaphases examined in primary
cultures. In subsequent passaging of the cultures, the pro-
portion of the cells with the marker rapidly diminished.
Both parents had apparently normal karyotypes. A
fibroblast cell line (DD3329) and lymphoblastoid cell lines
(DD3389 father, DD3390 mother) from both parents are
available from ECACC, Porton Down, Salisbury, Wilts,
SP4 0JG, UK.
Fluorescence in situ hybridisation (FISH) with nick
translated biotin or digoxigenin (Boehringer-Mannheim
UK) labelled centromere specific alpha satellite probes
were used based on a technique by Pinkel et al.3 The in situ
hybridisation was detected using one layer of FITC conju-
gated anti-avidin for biotin labelled probes or TRITC con-
jugated anti-digoxigenin for digoxigenin labelled probes.
Diamino-2-phenylindole (DAPI) at the rate of 0.05 mg/ml
suspended in an antifade solution (Vectashield, Vector
Labs, UK) was used to counterstain the chromosomes. A
Carl Zeiss Axioskop epifluorescent microscope fitted with
a Pinkel Fluorescent No 83 filter series (Chroma Technol-
ogy) was used to examine the hybridisation, while a cooled
charged couple device camera captured the images. Smart-
capture software (Digital Scientific, Cambridge, UK) was
used to analyse and visualise the digitised data. The normal
homologues acted as internal controls for the FISH. The
marker was screened with a library of alphoid centromere
specific probes at 1 × SSC in 50% formamide stringency,
but failed to hybridise to any of the probes, suggesting that
what appeared to be the marker’s primary constriction did
not contain alphoid repeats. This was confirmed when an
all centromere alphoid mixture used at low stringency (2 ×
SCC at room temperature) showed strong signal at all cen-
tromeres except for the marker (fig 1a).
Multiplex fluorescence in situ hybridisation (M-FISH)4
was performed on the marker using the Spectra Vision
Assay™ (Vysis). The protocol and probe set was as speci-
fied in the SpectraVision™ Assay protocol. The images
were captured on a Provis microscope (Olympus)
equipped with a motorised eight position turret with an
epifluorescence filter set designed for the fluors used.
Analysis was performed using M-FISH software supplied
by Perceptive Scientific International Ltd (PSI). Using
M-FISH, the marker was identified as being from chromo-
some 3.
FISH with the 3p and 3q subtelomere probes showed
hybridisation to the 3q subtelomere probe on the ends of
both arms (fig 1b), and wcp3 hybridised to the whole of the
marker (fig 1c). Subsequently CGH5 6 was applied using
DNA extracted from fetal skin and testis. The CGH
profiles were analysed using Vysis Quips CGH software
following hybridisations to 10 metaphases from each
tissue. The CGH profiles showed a significant gain of
material in distal 3q26 in fetal skin and in DNA extracted
from testis, a tissue not cultured in vitro. These profiles
suggested that the tetrasomy may not include the most dis-
tal 3q bands (q28 and q29); however, CGH profiles at the
extreme ends of chromosomes are known to be problem-
atical because of variable repeat sequences. Conventional
FISH with YAC 919f12 (3q29) confirmed that the marker
contained two copies of this sequence (fig 1d). Owing to
the instability of the marker in culture, we were unable to
perform any investigations with constitutive centromere
binding proteins. The conventional cytogenetics was
re-evaluated and suggested that the marker was an inverted
duplication from chromosome region 3q26.2→qter.
Molecular analysis was undertaken to check for the
biparental inheritance of the two normal chromosome 3
homologues and to find the parental origin of the marker
chromosome. DNA was extracted from fetal tissue and
peripheral blood from the parents. Primer sets were used to
detect polymorphic microsatellite repeat sequences along
the length of chromosome 3 and it was found that the
marker was maternal in origin and that the fetus had
inherited one normal chromosome 3 from each of his par-
ents and so excluded uniparental disomy 3.
As far as we are aware, the marker described here is the
first instance of an inverted duplication causing tetrasomy
for chromosome region 3q26.2→qter. Our patient had a
prenatally detected lumbosacral myelomeningocele,
Arnold-Chiari malformation with possible hydrocephalus,
and cystic renal dysplasia, and as a result was terminated at
18 weeks’ gestation. Arnold-Chiari malformation is seen in
approximately 1 in 1000 livebirths7 and is often associated
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with spina bifida with myelomeningocele and hydrocepha-
lus. Schinzel8 observed lumbosacral myelomeningocele
and Arnold-Chiari malformation in single incidences of
dup 3q23→25→q27 to qter. The marker breakpoint is
thought to be at 3q26.2, so the marker contains two copies
of 3q26.3, which Ireland et al9 considered to be the location
of the Cornelia de Lange syndrome gene and the duplica-
tion 3q syndrome critical region.10 The only features seen
which may be associated with de Lange or duplication 3q
syndromes, and may also be coincidental, were high arched
palate, a transverse crease on the right hand, and left cystic
renal aplasia.11 However, our case does prove the need to
do a detailed karyotype where upper and mid neural tube
defects are associated with other abnormalities.
Portnoï et al12 reported a similar supernumerary marker
chromosome in a healthy 22 year old male of normal intel-
ligence. He was not dysmorphic, but was referred because
of skin pigmentary anomalies showing hyperpigmented
brown macular streaks following the lines of Blaschko, the
onset of which occurred aged 10 to 12 years. The normal
skin fibroblasts showed no evidence of the marker, but
blood and hyperpigmented fibroblasts showed 30% and
6% cells respectively with the marker. Their marker was
analphoid, acrocentric with a breakpoint 3q27.1. The
lower level of mosaicism in vivo, proven tissue specificity,
and the smaller size of the marker may account for the
ameliorated phenotype in this patient compared with our
fetus. Another neocentromere located at 3q26 was
reported by Wandell et al13 and was observed in a father and
daughter, ascertained because of developmental delay in
the child along with hypertelorism, epicanthus, and a large
head. The father had borderline mental retardation. In this
case the normal centromeric region was deleted from the
chromosome 3 and had formed a small linear marker
chromosome. The two distal portions of the deleted 3 had
rejoined and a neocentromere was present at 3q26.
Interestingly, the neocentromere formed microtubule
associated kinetochores of the same size as other large
chromosome kinetochores, but was found to be weakly
positive with anticentromere (CREST) antibodies,
whereas the normal centromere on the small marker chro-
mosome showed a reduced kinetochore size but a strong
CREST antibody signal.
Our marker increases the haploid autosomal length of
the cell by about 1.5%, but is mosaic (57%) in primary
cultures. Other analphoid markers which give rise to tetra-
somies of the duplicated regions are also found to be
unstable in long term or fibroblasts cultures and are often
lost altogether.14 It seems remarkable that these markers
seem to be stable for many cell generations in vivo only to
be lost so rapidly in culture. This instability in vitro makes
it diYcult to judge how much eVect our marker had on the
phenotype, although we know that it was present in tissues
from two diVerent embryonic lineages (fetal skin and
testis).
The centromere is an essential structure of the chromo-
some and chromosomes lacking an active centromere will
eventually be lost during subsequent cell divisions. The
Figure 1 Molecular cytogenetic characterisation of the marker chromosome. Arrow indicates marker chromosome. (a) All
centromere alphoid mix. (b) 3q subtelomere probe (196f4) green, 3p subtelomere probe (dJ11286B18) red. (c) Whole
chromosome paint 3. (d) 3q29 probe (YAC 919f12).
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centromeric DNA is composed of highly repetitive A+T
rich sequences. The most investigated is alpha satellite
DNA which in humans is a 171 bp sequence tandemly
repeated many times such that between 2 and 4 Mb may be
present in a typical centromere.15 There seems to be no
similarity in the primary DNA sequence between species
and a lack of centromeric DNA conservation throughout
evolution makes it diYcult to equate its sequence to
function.16 Nonetheless, the repetitive nature of the DNA
and its A+T content appears to be a consistent feature of
many organisms and suggests that it is significant in
centromere function.17
Supernumerary marker chromosomes (SMCs) have a
prevalence of less than 1 in 1000 in the general population18
and in recent years in situ hybridisation using alpha satel-
lite probes allows the origin of most of the SMCs to be
identified. However, a minority do not hybridise to any of
the alphoid probes,19 but nevertheless these analphoid
markers are more or less stable in vivo and in vitro,14 20 sug-
gesting the presence of some centromeric properties,
unlike a true acentric chromosome. Two main explanations
have been suggested. Firstly, a complex rearrangement has
deleted the normal centromere to such an extent that,
although it can still function, the highly repetitive alpha
satellite probes cannot hybridise to it. Secondly, when the
normal centromere was lost, a latent centromere (or
neocentromere) was activated in a region not normally
associated with centromeric function.16 21 22 This latter
explanation is currently more favoured. Unfortunately, as
marker chromosomes tend to be found by chance, only the
endpoint is seen, never the intermediate steps nor the
mechanism in action by which the neocentromere may be
formed.23
Recent sequencing of the centromeric region of a chro-
mosome 10 derived analphoid marker has shown that
compared with the sequence of a normal centromere the
marker centromere is lacking in repetitive sequences. The
evidence from this neocentromere, and that from the deac-
tivation of centromeres in dicentric chromosomes, is more
proof that repetitive sequences per se do not dictate
centromere function. In sequencing the chromosome 10
neocentromere, it was found that although the A-T content
was no diVerent from that of the rest of the genome, there
was evidence of A-T rich islands but the significance of this
remains unknown. Nor did the neocentromere sequence
diVer significantly from the homologous region in the nor-
mal chromosome 10 and there was no major feature
present similar to known centromeric DNA. The complex
rearrangement hypothesis seems unlikely because so much
of the material that makes up a normal centromere is miss-
ing. So it does seem that a neocentromere forms from a
latent centromere activating in a region not known to be
centromeric.
Fewer than 35 neocentromeric markers have been
reported to date, but they are probably more frequent than
this figure suggests because of past diYculties in identifica-
tion, and it is likely more will be recognised and character-
ised in the future.14 Although at least 11 diVerent chromo-
somes have been implicated in the formation of
neocentromeres, it is interesting that our case is the third to
be reported in which a neocentromere has been activated
in the region near 3q26. Alphoid SMCs have duplicated
material from around the centromere, whereas neocentro-
meric markers will allow us to investigate the eVects of
duplicated genetic material from other chromosomal
regions.
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Why patients do not attend for their
appointments at a genetics clinic
EDITOR—When a patient does not attend a scheduled
appointment, or cancels so late that a replacement cannot
be found, there is a cost to the health care system in terms
of personnel time, extended waiting lists, and the loss of
potentially beneficial services to patients who miss their
visit. These costs are particularly important for genetics
clinics because a great deal of preparation is often required
before a clinic visit. Preparation may include sending out a
family history questionnaire from which a pedigree
diagram is constructed, and a review of the medical reports
and charts of the patient and other family members. In the
case of rare genetic conditions, a preliminary review of
publications/computer database search may be conducted
and research laboratories may be sought which would be
willing to receive patient samples. Furthermore, genetics
departments typically set aside at least an hour for each
new patient visit.
Failed appointment rates at community and university
medical clinics have been reported to range between 10
and 30%.1 2 Studies involving hospital clinics set in low
socioeconomic status populations have shown no show
rates in the upper end of this range, whereas family practice
clinics have reported fail rates as low as 5%.3
There is some evidence to suggest that missed appoint-
ments may be more likely among certain demographic
groups, such as young adults and adults with young
children,3 patients with lower socioeconomic and edu-
cational status, and those with larger families.1 Moreover,
geographical distance from the clinic or the inability to
obtain transport or both have been found to impede
appointment keeping.1 Sex and race have not been associ-
ated with compliance.1
Problems with communicating to patients about the
timing or nature of an appointment and in providing them
with information about their diagnosis may lead to missed
appointments,1 4 and a strong recommendation by the
referring physician has been shown to have a major benefit
on compliance.5–7
There may be a relationship between clinic attendance
rates and certain attitudinal factors. There is evidence that
patients are more likely to miss their appointments if they
perceive the appointment as less urgent1 3 or less helpful.4
Other potential psychological determinants of health care
use are variables from the Health Belief Model (HBM),8
including people’s perceived risk of developing a particular
health condition, perceived severity of the health condition,
and the perceived benefits, weighed against the costs, of an
associated health behaviour. The HBM has been applied to
a variety of health behaviours, such as breast cancer
screening practices.5 6 9 Patients’ beliefs about the personal
costs of medical clinic visits have also been shown to aVect
appointment keeping rates.10
The Children’s Hospital of Eastern Ontario (CHEO)
genetics clinic provides diagnostic and counselling services
to patients of all ages, including routine advanced maternal
age (AMA) counselling, personal or family history of
known genetic disease, and the assessment of subjects
whose condition is of unknown cause. At a time when
clinical demands on our programme are increasing, we
became concerned about the negative impact of no shows
on our ability to deliver eYcient and timely services. On
that basis we undertook a study in order to determine the
approximate rates of appointment cancellations and no
shows at diVerent Canadian genetics clinics, and to identify
factors that may be associated with missing clinic appoint-
ments. It was hoped that some associated variables might
be amenable to modification and lead to improved attend-
ance rates.
Twenty genetics clinics across Canada responded to a
survey regarding the frequency of broken appointments
(no shows and cancellations). The centres provide genetic
services free of charge as part of their respective provincial
health services. The non-attendance rate at the CHEO
genetics clinic was also determined. The clinics were sepa-
rated into three groups according to number of patients
seen per year; eight clinics had fewer than 500 patient visits
per year (small), eight saw between 500 and 2000 patients
per year (medium), and five clinics saw more than 2000
patients per year (large). Representatives of each genetics
clinic, usually a medical geneticist or clinic administrator,
completed a single page postal questionnaire designed to
assess their estimated rates of missed appointments, the
extent to which they considered these rates to be a
problem, and the strategies they used to reduce non-
attendance.
The CHEO genetics clinic operates according to the fol-
lowing pre-appointment procedure. Patients are referred to
the clinic by their physician. The clinic receptionist sched-
ules the appointment and, for non-AMA cases, sends the
patient a family history questionnaire and consent form for
release of medical information. Before the clinic appoint-
ment, the patient’s case is reviewed with relevant
documents and, for non-AMA patients, a family pedigree
is drawn. Non-AMA patients are contacted by telephone
24-48 hours before the scheduled visit in order to confirm
their attendance (AMA patients do not receive a reminder
telephone call). At all stages, patients are asked to cancel if
they do not plan to attend their clinic visit.
Data were collected by telephone from two groups of
patients originally scheduled for clinic between 1 February
1998 and 30 April 1999: 75 who attended their
appointments at the CHEO genetics clinic and 62 who
either did not show up for their appointments or who can-
celled with less than 12 hours notice. It should be noted
that late cancellations (less than 12 hours notice) were
counted as no shows because the ensuing consequences
were considered to be equivalent. The other surveyed
genetics clinics provided separate rates for cancellations in
general and for “pure no shows”.
A parent was interviewed if the index patient was under
18 years of age. All participants (total n=137) were English
or French speaking and lived in the Ottawa-Carleton
regional catchment area of approximately 1 million.
Two slightly diVerent versions of the survey instrument
were used, one for each group of participants. The instru-
ment was developed by the authors to assess information in
four main content areas: (1) demographics (age, marital
status, children, education, family income, language
spoken at home); (2) referral and genetic service
information (reason for referral, the degree to which
patients understood these reasons, the quality of explana-
tions provided by referring physicians regarding these
reasons, whether or not patients were referred at their own
request, and the degree to which referring physicians
recommended the genetics appointment); (3) environmen-
tal factors (transport, distance from home to the clinic, and
arrangements for child care and taking time oV work); and
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(4) psychosocial factors (including perceived importance
of the clinic visit as well as Health Belief Model variables).
A variety of response formats were used, including yes/no,
Likert scales, and open ended questions which were later
categorised for analysis. The bilingual survey took approxi-
mately 15 minutes to complete and was administered by a
trained research assistant.
Descriptive statistics were performed to assess the nature
of the scheduled appointment at the clinic, as well as the
reasons provided by non-attendees for missing their sched-
uled visit. Attendees and non-attendees were compared on
the basis of variables in the four main content areas
described above, using independent sample t tests and chi-
square analyses as appropriate. Two by two factorial analy-
ses of variance were also conducted in order to assess
potential interaction eVects between group membership
and other relevant variables.
Representatives of 27 Canadian genetics clinics were
sent copies of the no show survey and 20 (74%) completed
and returned the survey. A summary of no show and can-
cellation rates for the three sizes of clinics is provided in
table 1; data from the CHEO genetics clinic are included.
Approximately half the data were estimated while the
remainder were based on actual records of missed visits.
The rate of combined no shows and cancellations at indi-
vidual centres ranged between 2% and 25%, with an over-
all mean of 12%. Non-attendance rates were perceived as a
problem by most genetics clinics across Canada. However,
large and medium centres perceived a greater problem
than did smaller centres, despite having lower non-
attendance rates (mean rates were 10.8%, 10.0%, and
15.1% for large, medium, and small centres, respectively).
If cancellations are eliminated, the mean overall rate of no
shows is 6.6%.
For comparison purposes, failed appointment rates were
obtained for a variety of other medical clinics at CHEO,
including audiology, child development service, neuro-
muscular medicine, occupational therapy, physiotherapy,
rehabilitation medicine, speech/language, and spina bifida
clinics. The no show rates for 1998 ranged between 6% and
15%, yielding an overall mean of 11%.
The no show prevention strategies cited by the genetics
clinics across Canada were compared. The centres were
subdivided by their total non-attendance rate into three
groups: low rate (5-11%), medium rate (12-18), and high
rate (19-25%). The impact of the strategy most commonly
cited (reminder phone call) could not be assessed because
it was used virtually universally. However, the strategy of
sending reminder letters to the patient was used most often
by centres which reported low non-attendance rates.
A total of 258 households (120 potential attendees and
138 potential non-attendees) were telephoned regarding
the study, of which 137 (53%) participated in the survey
(75 attendees and 62 non-attendees). Among the subjects/
families who did not participate, 24 (20%) could not be
reached because of repeated busy signals or answering
machines (no messages were left). Another 24 (20%) asked
the interviewer to phone back at another time, and gave a
similar response upon subsequent phone calls, even when
the call was made at a prearranged time. Nineteen (17%) of
the telephone numbers were either not in service or were
wrong numbers, and two of the households (2%) reported
that the patient (or parent of the patient) lived elsewhere
and did not have a telephone. An additional 12 (10%) sub-
jects had a language barrier. Finally, 30 (25%) of the non-
participants stated that they were not interested in doing
the survey. There were more no shows (76; 63%) than
clinic attendees (45; 37%) among the households that did
not participate in the survey.
Table 2 provides a description of participants on the
basis of key demographic variables. The average age of
respondents was 36 years; where the respondent was a par-
ent of the patient, the average age of patients was 5 years.
The large majority of respondents were married/common
law (84%) and had children (77%).
Attendees and non-attendees did not diVer significantly
on the basis of age (p=0.21), marital status (p=0.59), pres-
ence of children (yes or no; p=0.21), number of children
(p=0.09), language spoken most often at home (p=0.11),
or family income (p=0.11). Two demographic variables did
yield significant results. Non-attendees had a lower mean
level of education than attendees (p<0.05), and patients
who were planning to have children (or more children)
were more likely to have attended their clinic visits than
those who were not planning on starting or expanding their
families (p<0.05) (table 3).
Table 3 outlines the main reasons given by non-
attendees for missing appointments. The reasons diVered
significantly between those who were referred for prenatal
diagnosis (PND) services and those referred for other
reasons (p<0.05). The main reasons given by all
Table 1 Rates of no shows and cancellations at Canadian genetics clinics
Size of centre*
Small
(n=8)
Medium
(n=8)
Large
(n=5)
Total
(n=21)
Mean no show rate (%) 9.3 4.7 5.7 6.6
Mean cancellation rate (%) 7.3 5.9 7.0 6.7
Mean combined no show and
cancellation rates (%)
15.1 10.0 10.8 12.0
% of centres that indicated
non-attendance is a problem
50 75 80 67
*Small = <500 visits/year; medium = 500–2000 visits/year; large = >2000 visits/
year.
Table 2 Demographic characteristics of the sample
Variable
Attendees (n=75)
Non-attendees
(n=62)
No
% of
group No
% of
group
Age of respondent
20–29 years 6 8 9 15
30–34 years 12 16 13 22
35–40 years 43 58 34 56
>40 years 13 18 4 7
Marital status
Married/common law 65 87 50 81
Single 5 7 7 11
Divorced, separated, or widowed 5 7 5 8
No of children
0 21 28 10 16
1 24 32 18 29
2–3 27 36 29 47
>3 3 4 5 8
Planning more children*
Yes 42 56 28 45
No 23 31 31 50
Language spoken at home
English 48 64 42 68
French 19 25 8 13
Both English and French 3 4 8 13
Other 5 7 4 6
Education†
Less than high school 4 5 4 7
High school 15 20 20 32
Some college or university 12 16 15 24
College or undergraduate degree 30 40 17 27
Graduate degree 14 19 6 10
Family income‡
<$20 000 6 9 4 8
$20 000–$40 000 16 25 18 36
$40 000–$75 000 19 30 20 40
>$75 000 23 36 8 16
*Attenders had a higher overall education level than non-attenders, t (135) =
−2.29, p<0.05.
†Attenders were more likely to be planning more children than non-attenders,
÷2(2) = 6.58, p<0.05.
‡Numbers are smaller for this variable owing to missing data.
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non-attendees for missing appointments were being “too
busy” or unable to get time oV work, forgetting the
appointment or having a scheduling conflict, and believing
the appointment to be non-mandatory or unimportant.
Reasons associated with the PND group included being
unsure or afraid of the risks associated with amniocentesis,
having recently suVered a miscarriage, experiencing morn-
ing sickness on the day of the appointment, and wanting to
wait for laboratory test results (such as maternal serum
screening) before deciding whether to be seen at the genet-
ics clinic.
Slightly less than half (46%) of all participants were
scheduled to meet a medical geneticist at the clinic, and the
remainder were scheduled to meet a genetic counsellor.
There was no significant diVerence between attendees and
non-attendees with respect to the type of health profes-
sional they were scheduled to see at the clinic (p=0.86).
Approximately half (51%) of all participants were sched-
uled for appointments associated with advanced maternal
age prenatal screening. Another 42 patients (31%) were
being seen in order to seek a specific diagnosis; 23 patients
(17%) were scheduled to discuss genetic risk information/
carrier screening, and only two respondents (1.5%)
indicated that they did not know the reason for their refer-
ral to the genetics clinic. Attendees and non-attendees did
not diVer on the basis of their reasons for referral to the
clinic (p=0.46). Moreover, attendees were no more or less
likely than non-attendees to have been referred to the clinic
at their own request (p= 0.92), to understand well the
reasons for their referral (p=0.17), or to indicate that their
physicians had highly recommended the appointment
(p=0.15) or had explained the reason for referral well
(p=0.13).
It was hypothesised that some of the referral related
variables (table 4) may have been confounded with
patients’ education level, and so additional analyses were
performed in order to separate these eVects. A dichoto-
mous version of the education variable (originally in a Lik-
ert scale format) was created by cutting scores at the
median, yielding the two categories of “high” (at least a
college diploma or university undergraduate degree) and
“low” (high school education or less). Two by two analyses
of variance showed a significant group by education level
interaction with regard to patients’ reported degree of
understanding of the reasons for their referral (p<0.05)
and the reported quality of the explanation of these reasons
by their referring physicians (p<0.05). An examination of
cell means indicated that among patients with a higher
education level, attendees understood their reasons for
referral better and claimed their physicians had explained
these reasons better than did non-attendees. No such
group diVerence existed among patients with a lower edu-
cation level.
We hypothesised that patients with a higher education
level would more likely have been referred to the genetics
clinic at their own request, because of their presumed
greater knowledge about genetic health services. A
chi-square analysis showed this not to be the case
(0.55<p<0.60).
The relationship between non-attendance and environ-
mental variables is shown in table 5. Patients who reported
having to arrange for child care in order to attend a clinic
visit were more likely to have missed their scheduled
appointments than those who indicated no such require-
ment (p<0.05). Although having to take time oV work to
attend a clinic visit was not associated with a greater likeli-
hood of non-attendance (0.70<p<0.75), those respond-
ents who were not paid for such time oV were more likely
to have missed their appointments than those who were
able to take paid leave from work to attend the clinic
(p<0.05). No significant diVerences between attendees and
non-attendees were found in methods of transport to the
clinic (0.20<p<0.25) or travel time to the clinic
(0.10<p<0.15). Failure to make contact by telephone to
remind the patient of the clinic visit occurred in 10 of the
no shows and none of the attendees.
The relationship between non-attendance and psychoso-
cial variables is shown in table 6. Respondents who
attended their appointments perceived the clinic visit to be
more important than respondents who did not attend
(p<0.01). With regard to the Health Belief Model
variables, no significant group diVerences were found in
terms of perceived severity of the health condition (or
potential health conditions) which were to be discussed
during the appointment (0.65<p<0.70). Moreover, the
two groups did not diVer significantly with respect to their
perceived risk of having (or eventually developing) these
health conditions (0.60<p<0.65).
Non-attendance was significantly related to perceived
benefits and disadvantages of the genetics appointment.
Specifically, patients who missed their appointments
perceived the potential benefits of the clinic visit to be less
Table 3 Reasons given by non-attendees for missing genetics clinic
appointments
Reason given for missing appointment
Reason for referral to genetics
PND* (n=31)
Non-PND*
(n=31)
No % No %
Too busy/no time oV work 8 26 14 45
Forgot/scheduling conflict 4 13 7 23
Believed appointment was
non-mandatory or unimportant
4 13 1 3
Wanted to wait for lab results 3 10 1 3
Other 1 3 6 19
Unsure/afraid re risks of amniocentesis 4 13 1 3
Recent miscarriage 4 13 0 0
Morning sickness on day of
appointment
3 10 1 3
PND = prenatal diagnosis.
*Reasons diVered between PND and non-PND patients: ÷2(7) = 15.64, p<0.05.
Table 4 Comparison of attendees and non-attendees on referral/genetic
service variables
Variable
Attendees (n=75)
Non-attendees
(n=62)
No
% of
group No
% of
group
Reason for referral to genetics
Prenatal diagnosis 39 52 31 50
Carrier testing/risk information 12 16 11 18
Diagnostic evaluation 24 32 18 29
Other 0 0 2 3
How well was reason explained?*
Very poorly 0 0 1 2
Poorly 2 3 3 6
Adequately 8 14 10 20
Well 14 25 12 25
Very well 33 58 23 47
How well did you understand the reason?*
Not at all 0 0 2 3
Poorly 2 3 2 3
Adequately 3 5 4 7
Well 9 15 12 22
Very well 48 77 35 65
Referred at own request
Yes 26 35 22 36
No 49 65 40 64
How strongly referring physician recommended the genetics appointment*
Not strongly 5 8 7 13
Somewhat strongly 20 30 22 40
Quite strongly 15 23 9 16
Very strongly 25 38 16 29
Recommended against 1 1 1 2
*Numbers are smaller for these variables owing to missing data.
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important (p<0.01) and the potential disadvantages to be
more important (p<0.01) than patients who kept their
appointments.
The results of this study help to quantify the problem of
missed appointments at genetics clinics across Canada.
Over a one year period, approximately 11% of patients
scheduled for visits at genetics clinics either cancelled or
did not show up for their appointments. When cancella-
tions are eliminated, this number decreases to 6%,
representing the rate of “pure no shows”. In comparison,
11% of patients failed to show up for their appointments at
other non-genetics outpatient clinics at the Children’s
Hospital of Eastern Ontario (CHEO). These values are
relatively low compared with the 10-30% range frequently
reported.1 2 Family practice centres have fewer broken
appointments than adult medical centres.3 Perhaps the
family orientation of paediatric and genetics clinics is more
akin to family practice and reduces the likelihood that
appointments will not be kept.
It should be noted that in the survey of the CHEO
genetics clinic, the non-attendees group included cancella-
tions with less than 12 hours notice which, owing to their
negative consequences, were considered equivalent to no
shows. This distinction between early and late cancella-
tions was not requested from the other genetics clinics sur-
veyed in this study (they were simply asked to report two
separate numbers for “pure” no shows and cancellations,
respectively). If late cancellations had been included in the
no show rates provided by the other clinics, the resulting no
show rates would probably have been somewhat higher
than reported.
Although an 11% rate of failed appointments at
Canadian genetics clinics is comparatively low, it is still a
sizeable barrier to the optimal provision of genetic health
services. Unlike many clinics, where multiple bookings are
common and visits are usually short, genetics clinics
expend extensive resources for pre-appointment planning
and generally allocate an hour for a clinic visit.
This study suggests a number of factors which may con-
tribute to the problem of missed appointments. The most
commonly stated reasons for missed appointments at the
CHEO genetics clinic were scheduling conflicts and
inability to get time oV work. As these are predictable fac-
tors, it is surprising that more than half of respondents
cited them, despite being called 24-48 hours before the
appointment. The question arises as to whether the
answers provided by patients over the telephone concealed
underlying reasons such as anxiety, confusion, or personal
belief systems, which lead to last minute decisions not to
attend, or were too personal to admit to the secretary or the
research assistant.
Some psychosocial variables appeared to contribute to
the non-attendance rate. Patients who attended their
scheduled appointments thought their visit to the genetics
clinic to be more important than those who did not attend.
This is similar to previous research which has found
perceived urgency of medical clinic visits to be significantly
related to compliance,1 3 though urgency and importance
may represent relatively distinct constructs.
Patients who attended the clinic also perceived more
benefits and fewer barriers associated with their appoint-
ments than did non-attendees. This supports the Health
Belief Model8 and previous research, which has indicated
such health beliefs to be important predictors of health
behaviours.6 9 10 Apparently, for non-attendees, the poten-
tial costs of the clinic visit (such as the anxiety or guilt that
may be experienced after learning of one’s carrier status)
outweighed the possible benefits (such as relief from
uncertainty or clarification of one’s options). In contrast,
the perception of the benefits of attending the genetics
clinic appeared to outweigh the perceived disadvantages
for those who kept their appointments.
We found that certain psychosocial factors may play a
role in non-attendance, but not all of the anticipated eVects
were found. For example, perceived severity of the health
condition (or potential health condition) for which patients
were referred to the clinic, along with the perceived risk of
having or eventually facing that health condition, were
unrelated to clinic attendance. The former result is not
surprising, given that the “perceived severity” component
of the Health Belief Model has been shown to have limited
value in predicting a variety of health behaviours.11
However, a high perceived risk has been found to predict a
number of health behaviours, including mammography,5 12
genetic testing for susceptibility to breast cancer,13 14 and
Table 5 Comparison of attendees and non-attendees on environmental
variables
Variable
Attendees (n=75) Non-attendees (n=62)
No
% of
group No
% of
group
Have to arrange for child care to attend the clinic?*
Yes 12 16 19 31
No 63 84 43 69
Have to take time oV work to attend the clinic?
Yes 39 52 30 49
No 36 48 31 51
If yes, paid for this time oV?*
Yes 23 60 10 33
No 15 40 20 67
Method of transport to clinic
Own vehicle 65 87 48 77
Get a ride 7 9 6 10
Bus 3 4 6 10
Walk 0 0 2 3
Travel time to clinic
<15 minutes 4 5 4 7
15–30 minutes 35 47 24 39
30–45 minutes 18 24 10 16
45–60 minutes 7 9 7 11
>60 minutes 11 15 17 27
*p<0.05.
Table 6 Comparison of attendees and non-attendees on psychosocial
variables
Variable
Attendees (n=75)
Non-attendees
(n=62)
No
% of
group No
% of
group
Perceived importance of clinic visit*
Not at all important 1 1 6 10
Of little importance 4 5 5 8
Neutral 8 11 10 16
Somewhat important 16 21 2 3
Very important 46 62 27 43
Perceived severity of genetic condition
Not at all serious 8 11 11 18
Of little severity 14 19 13 21
Neutral 18 24 5 8
Somewhat serious 12 16 14 23
Very serious 22 30 18 30
Perceived risk of genetic condition
Very low 16 21 19 32
Somewhat low 13 17 11 18
Medium 26 35 12 20
Somewhat high 11 15 7 12
Very high 9 12 11 18
Perceived benefits of clinic visit*
No benefits 1 1 7 12
Few benefits 4 5 4 7
Neutral 10 13 10 17
Some benefits 14 19 13 22
Many benefits 46 62 25 42
Perceived importance of disadvantages of clinic visit*
Not at all important 56 74 30 52
Of little importance 6 8 5 8
Neutral 8 11 8 14
Somewhat important 2 3 3 5
Very important 3 4 12 21
*p<0.01.
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cystic fibrosis carrier screening.15 One possible explana-
tion for the absence of such an eVect in this study lies in
the nature of the “health condition” in question. Previous
research has examined patients’ health beliefs with respect
to a single, specific illness or procedure. In the present
study, patients were referred to the genetics clinic for a
variety of reasons; consequently, a more general question
regarding perceived risk was included in the survey which
permitted patients to respond according to their own
situation. This lack of specificity may have led to a
varied interpretation of the question, thus reducing the
strength of the “perceived risk” and “perceived severity”
variables.
If the above health beliefs are the true reasons that
underlie the stated explanations (for example, could not
get time oV work) given by some patients for missing their
appointments, this holds important implications for the
provision of adequate public education regarding genetics
related health issues. It is widely accepted that a thorough
explanation of the risks and benefits associated with a
given medical intervention is required in order for patients
to provide informed consent. It is not clear how such
standards extend to diVerent contexts, such as a genetics
clinic appointment. Greater public awareness of the serv-
ices provided by genetics professionals will provide
patients with a balanced and accurate understanding of
the importance, risks, and benefits of a scheduled
appointment. The fact that patients with a higher educa-
tion level (at least an undergraduate university degree)
were more likely to attend their appointments than those
with less education reinforces this need for greater public
education. Studies have found that people of lower
educational status are more likely to miss their medical
appointments.1 People with a university education
probably have greater access to (and experience with)
health related information found in scientific journals,
books, and news magazines. Delivery of health infor-
mation to those who have less formal education may
facilitate the use of health services by more subjects and
families. An alternative interpretation of the education
eVect is equally possible: those working in higher level
positions may simply have greater job flexibility and may
thus have had less diYculty attending their clinic appoint-
ments.
Other demographic variables, including age, marital
status, number of children, language spoken most often at
home, and family income, did not diVerentiate between
attendees and non-attendees. This is encouraging, in that
most of these variables are not easily targeted by clinic
based interventions to improve attendance rates. One
exception may be language, which has been subject to
limited previous research and is an important variable to
assess in a country with two oYcial languages; in our
genetics clinic services are regularly provided in
French and English. Our finding that language does not
appear to be a barrier to attendance is encouraging, but
the question may need to be addressed for patients who do
not speak either oYcial language. People not fluent in
English or French were excluded from the sample. There
were 12 people who did not participate in the survey
because of a language barrier. Nine of these were in the
group who missed their appointments, so this is an
issue that may merit further investigation, as a
language barrier would represent a potential target for
intervention.
It should be noted that the lack of significant results for
many demographic variables may be in part because of the
narrow response ranges associated with the corresponding
survey items. For example, the mean age of survey
respondents was quite young (36 years) and people over
the age of 45 were virtually absent from the sample. Stud-
ies of adult non-genetics clinics would encompass a wider
range of patient ages, leading to a greater likelihood of sig-
nificant age eVects. Moreover, the majority of participants
were married (84%) and had children (77%). Only 10 par-
ticipants (7%) reported a family income of less than
$20 000, indicating a clear under-representation of low
socioeconomic status families. The lack of any association
with family income may also reflect universal access under
the Canadian health care system. Previous studies showing
significant eVects of socioeconomic status have generally
been conducted in the United States, a country which lacks
universal health care.
The quality of information given to patients by their refer-
ring physicians about the referral to genetics was not associ-
ated with the overall rate of missed appointments. However,
it did play a role in the specific subgroup of patients with a
higher education level. Among those participants, the
attendees reported that they understood the reasons for their
referral better, and that their physicians had explained these
reasons better, than those who did not attend. It appears that
while patients with a higher education level are more likely to
attend their appointments, they are also more likely to
require thorough explanations of the rationale for the
appointment before deciding whether or not to attend. Thus
there may be some argument for improving the quality of
pre-appointment information provided to patients by health
care professionals.
These results lend some support to previous research
indicating that patients who understand the reasons for
their referral relatively well are more likely to attend their
clinic appointments.4 Contrary to previous studies,5 7 how-
ever, the degree to which the referring physician recom-
mended the genetics clinic appointment did not influence
the likelihood of attendance.
Finally, although diYculties with scheduling conflicts,
transport, and inability to take time oV work may often at
least in part conceal more important underlying reasons for
non-attendance, they may sometimes compromise ap-
pointment keeping. Patients who had to arrange for child
care in order to attend the clinic were more likely to miss
their appointments, and this confirms previous results
indicating that broken medical appointments are more
likely among larger families and those with younger
children.1 3 The need for child care is an important barrier
to the provision of health services at a genetics clinic
because families comprise most of the patient population.
Provision of day care facilities within medical institutions
might prove cost eVective, given that all clinics experience
a similar, if not higher, no show rate.
The need to take time oV work for a clinic appointment
does not appear to present a significant barrier to appoint-
ment keeping, except for those who are required to take
time oV without pay. This problem could be solved if clin-
ics extended their hours of operation, so as to accommo-
date work schedules.
Contrary to previous research,1 other practical matters
such as distance from the clinic and available method of
transport were unrelated to rates of failed appointments at
the CHEO genetics clinic. Such eVects were lacking,
despite the fact that patients reported a wide range of travel
times, including 28 patients (20%) who indicated that it
took them more than an hour to get to the hospital. It may
be that once the patient has made an assessment that the
appointment is important, travel time may be irrelevant.
We cannot draw any conclusions regarding any eVects of
transport method, because the vast majority (83%) of
respondents drove their own vehicles to the clinic. This
probably reflects the high mean socioeconomic status of
the current sample; studies involving less privileged people
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might show that lack of a convenient mode of transport is a
significant obstacle in appointment keeping.
Our patient sample does not reflect the general
population and is a limitation of the present study.
Participants were highly educated and reported relatively
high family incomes, which may account for the slightly
lower rate of non-attendance at this clinic, as compared
with the rates seen in previous studies which have focused
mainly on low socioeconomic status populations. It is
possible that factors other than those we have evaluated, or
that we have found negative in our sample, may contribute
to non-attendance rates in patients with a lower
educational and socioeconomic status. Nevertheless, our
results support some findings of previous studies which
included low socioeconomic status populations.3 4 10
Moreover, the fact that our non-attendance rate was con-
sistent with those reported by genetics clinics across
Canada suggests that these rates reflect an accurate
portrayal of the problem in the context of genetics health
care in Canada.
Other limitations of this study include the limited gener-
alisability of results to the United States health care system,
as well as the telephone interview methodology. For
non-attendees in particular, the latter approach may have
restricted the degree of candour in participants’ survey
responses; future studies may benefit from the use of a
more anonymous data collection format. Finally, approxi-
mately half of the surveyed genetics clinics provided
estimated as opposed to actual rates of non-attendance.
Estimation may not accurately reflect no show rates; how-
ever, a comparison of means indicated that the actual and
estimated numbers were similar.
Results of this study suggest a number of potential
targets for improving attendance rates at genetics and other
outpatient medical clinics. Better education of patients
about their medical condition, the nature and purpose of
specific options available to them, and the costs and
benefits associated with such options, is clearly indicated.
To be maximally eVective, such education should come
from a variety of sources, including the mass media, pam-
phlets distributed to pharmacies and medical clinics of all
types, and, most importantly, open and detailed communi-
cation between patients and physicians. Some clinics could
also attempt to extend or modify their hours of operation
and on site child care initiatives could be explored. These
larger scale approaches, in combination with more
traditional methods such as telephone and mailed appoint-
ment reminders, may help to replace lengthy waiting lists
and wasted physician time with more eYcient and far
reaching health care services.
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CORRECTION
In the April 2000 issue of the journal, in the paper by
Mortier et al on “Report of five novel and one recurrent
COL2A1 mutations with analysis of genotype-phenotype
correlation in patients with a lethal type II collagen disor-
der”, the mutation T1191N should have been T1190N
throughout.
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